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ABSTRACT OF DISSERTATION 
Autologous Peripheral Nerve Grafts to the Brain for the 
Treatment of Parkinson’s Disease  
Parkinson’s disease (PD) is a disorder of the nervous system that causes problems 
with movement (motor symptoms) as well as other problems such as mood disorders, 
cognitive changes, sleep disorders, constipation, pain, and other non-motor symptoms. 
The severity of PD symptoms worsens over time as the disease progresses, and while 
there are treatments for the motor and some non-motor symptoms there is no known 
cure for PD. Thus there is a high demand for therapies to slow the progressive 
neurodegeneration observed in PD. Two clinical trials at the University of Kentucky 
College of Medicine (NCT02369003, NCT01833364) are currently underway that aim to 
develop a disease-modifying therapy that slows the progression of PD. These clinical trials 
are evaluating the safety and feasibility of an autologous peripheral nerve graft to the 
substantia nigra in combination with Deep Brain Stimulation (DBS) for the treatment of 
PD. By grafting peripheral nerve tissue to the Substantia Nigra, the researchers aim to 
introduce peripheral nerve tissue, which is capable of functional regeneration after injury, 
to the degenerating Substantia Nigra of patients with PD. The central hypothesis of these 
clinical trials is that the grafted tissue will slow degeneration of the target brain region 
through neural repair actions of Schwann cells as well as other pro-regenerative features 
of the peripheral nerve tissue.   
This dissertation details analysis of the peripheral nerve tissue used in the above 
clinical trials with respect to tissue composition and gene expression, both of injury-naive 
human peripheral nerve as well as the post-conditioning injury nerve tissue used in the 
grafting procedure. RNA-seq analysis of sural nerve tissue pre and post-conditioning show 
significant changes in gene expression corresponding with transdifferentiation of 
 
Schwann cells from a myelinating to a repair phenotype, release of growth factors, 
activation of macrophages and other immune cells, and an increase in anti-apoptotic and 
neuroprotective gene transcripts. These results reveal in vivo gene expression changes 
involved in the human peripheral nerve injury repair process, which has relevance beyond 
this clinical trial to the fields of Schwann cell biology and peripheral nerve repair. To assess 
the neurobiology of the graft post-implantation we developed an animal model of the 
grafting procedure, termed Neuro-Avatars, which feature human graft tissue implanted 
into athymic nude rats. Survival and infiltration of human graft cells into the host brain 
were shown using immunohistochemistry of Human Nuclear Antigen. Surgical methods 
and outcomes from the ongoing development of this animal model are reported. To 
connect the results of these laboratory studies to the clinical trial we compared the 
severity of motor symptoms before surgery to one year post-surgery in patients who 
received the analyzed graft tissue. Motor symptom severity was assessed using the 
Unified Parkinson’s Disease Rating Scale Part III. Finally, the implications and future 
directions of this research is discussed. In summary, this dissertation advances the 
translational science cycle by using clinical trial findings and samples to answer basic 
science questions that will in turn guide future clinical trial design. 
 
KEYWORDS: Neurodegeneration, Neuroprotection, Neuroregeneration, Schwann cell, 
Clinical trial 
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Chapter One: Introduction 
Parkinson's Disease and Peripheral Nerve Grafting to the CNS1 
Parkinson’s Disease and Its Current Therapies 
Parkinson’s disease (PD) is a disorder of the nervous system that causes problems 
with movement (motor symptoms) as well as other problems (non-motor symptoms). The 
motor symptoms of PD are the most widely-known complications of the disease and 
include slow movement (bradykinesia), rigidity, and/or a tremor in body parts at rest 
(resting tremor). The non-motor symptoms of PD include cognitive impairment, 
autonomic dysfunction, sleep disorders, constipation, depression, olfactory dysfunction, 
and pain.  
PD primarily affects the elderly. The average age of PD diagnosis is in the late 
fifties, and the risk of being diagnosed with PD increases with age. (Pringsheim, Jette, 
Frolkis, & Steeves, 2014) PD affects over 630,000 people in the United States (US), leading 
to the total economic burden of 14.4 billion per year in 2010 (Kowal, Dall, Chakrabarti, 
Storm, & Jain, 2013). Because PD primarily affects the elderly, and because average age 
of the US population is rising, these numbers are projected to increase to an estimated 
1.34 million people in the US alone by 2050 (Kowal et al., 2013). 
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The severity of PD symptoms worsens over time as the disease progresses, and 
while there are treatments for the motor and some non-motor symptoms there is no 
known cure for PD. PD is classified as a neurodegenerative disorder, meaning that it is 
caused by the progressive degeneration and death of cells of the nervous system. In PD, 
loss of dopamine-producing cells in the substantia nigra region of the midbrain leads to 
decreased function of the nigrostriatal pathway and dysregulation of the basal ganglia 
motor circuit, leading to the motor symptoms of PD (Kordower et al., 2013). Other regions 
of the nervous system also degenerate in PD and contribute to the non-motor symptoms 
of the disease. The Braak Staging hypothesis states that neurodegeneration in PD is first 
observed in the enteric nervous system (as well as the olfactory bulb) (Braak et al., 2003) 
and progresses in an anatomically connected pattern to affect the dorsal motor nucleus 
of the vagus, basal forebrain, substantia nigra, mesial temporal cortex, and in late-stage 
disease the cerebral cortex (Halliday et al., 2010). Progressive degeneration of these brain 
regions is correlated with the progression of clinical symptoms (De Pablo-Fernandez, 
Lees, Holton, & Warner, 2019; Wolters, 2006). 
Unlike most other neurodegenerative disorders, the motor symptoms of PD can 
be effectively treated pharmacologically. The primary medical treatment for PD is 
levodopa (LeWitt, 2008), which is often given in combination with other medications to 
increase its effectiveness. Levodopa, or L-DOPA, is the biosynthetic precursor to 
dopamine in the human body. Levodopa administered orally in pill form can cross the 
blood-brain barrier and enter the striatum, where it is converted to dopamine. This 
supplements the level of dopamine in the striatum which would be provided by an intact 
3 
nigrostrial pathway but which is reduced in PD. In doing so levodopa reduces the severity 
of motor symptoms in PD. Other medications given in combination with levodopa can 
increase this effectiveness. For example, carbidopa is an inhibitor of the enzyme aromatic-
L-amino-acid decarboxylase (DOPA decarboxylase or DDC), which converts levodopa to 
dopamine. Carbidopa does not cross the blood-brain barrier, so it inhibits the conversion 
of levodopa in the periphery but not in the CNS, leading to more levodopa being available 
in the brain. This increases the effectiveness of levodopa medication (Koller, Hutton, 
Tolosa, Capilldeo, & Group, 1999). Because of this synergistic action, carbidopa + 
levodopa (brand name Sinemet) combination therapy is the first-line treatment for PD 
(Yeh et al., 1989). 
However, the severity of motor symptoms in PD worsens over time even if PD is 
medically treated (De Pablo-Fernandez et al., 2019). Because of this worsening of 
symptoms, higher doses of medication are required to manage the symptoms of PD over 
time (LeWitt, 2008). This leads to negative complications of medical therapy such as 
dyskinesia; or uncontrolled, involuntary movement (Kumar, Mishra, Dwivedi, & 
Subramaniam, 2015). Fortunately, more effective therapies for PD now exist. 
Parkinson’s disease is also distinct from other neurodegenerative diseases in that 
it can be effectively treated using a surgical approach. Deep Brain Stimulation (DBS) is an 
FDA-approved surgery for the treatment of PD (Benabid, Chabardes, Mitrofanis, & Pollak, 
2009). This surgery involved the implantation of stimulating electrodes to targeted brain 
regions. In the case of PD, the target are the basal ganglia regions of either the internal 
segment of the globus pallidus (GPi) or the subthalamic nucleus (STN) (Williams, Foote, & 
4 
Okun, 2014). By stimulating these brain regions, the functional signaling of the basal 
ganglia is altered and the severity of motor symptoms is reduced (Perlmutter & Mink, 
2006). These electrodes are connected through a subcutaneous lead wire to a 
programmable stimulator + battery usually placed below the skin of the chest. This allows 
for the frequency and pattern of stimulation to be remotely programmed in the clinic to 
fine-tune the control of a patient’s motor symptoms and to adjust the programming as 
PD progresses and the severity of motor symptoms increases (Volkmann, Moro, & Pahwa, 
2006). For this reason DBS has primarily replaced surgical lesioning of basal ganglia 
structures as the surgical treatment of choice for the treatment of PD (Marsden & Obeso, 
1994), and has been shown to be more effective than the best medical therapy for the 
treatment of PD (Weaver et al., 2009). 
While effective, the medical and surgical treatments for PD have limitations. 
Medication and surgery can treat the motor symptoms of PD, they are not known to slow 
or reverse the degenerative process of the disease (Hilker et al., 2005). Furthermore, most 
non-motor symptoms of PD are not addressed by either of these therapies. Thus there 
exists a high demand for disease-modifying therapies to slow or reverse the progressive 
neurodegeneration observed in PD. 
The DBS+ Clinical Trials 
Two clinical trials at the University of Kentucky College of Medicine 
(NCT02369003, NCT01833364) are currently underway that aim to develop a disease-
modifying therapy that slows the progression of PD. These clinical trials are evaluating the 
5 
safety and feasibility of an autologous peripheral nerve graft to the Substantia Nigra in 
combination with DBS for the treatment of PD. Figure 1.1 illustrates the nerve graft 
procedure. By grafting peripheral nerve tissue to the Substantia Nigra the researchers aim 
to introduce peripheral nerve tissue, which is capable of functional regeneration after 
injury, to the degenerating Substantia Nigra of patients with PD. (van Horne et al., 2017) 
The central hypothesis of these clinical trials is that the grafted tissue will slow 
degeneration of the target brain region through neural repair actions of Schwann cells as 
well as other pro-regenerative features of the peripheral nerve tissue.  
The combination of DBS with delivery of an additional therapy is termed “DBS+” 
by the investigators. DBS+ utilizes DBS surgeries as a platform for the delivery of 
therapeutics to the CNS. The same stereotaxic hardware used to implant DBS electrodes 
is also effective in delivering other treatments to deep brain regions. In addition, these 
therapies can be delivered during the same surgical and anesthesia events as DBS alone. 
In these trials, PD patients receive both the standard of care DBS surgery as well as an 
experimental disease-modifying therapy (i.e. peripheral nerve tissue), but the delivery of 
other therapeutics using DBS+ is possible as well. 
A core practice of this clinical trial is the pre-lesioning of nerve graft tissue two 
weeks prior to implantation. This pre-lesioning practice is also known as a conditioning 
injury, and has been the subject of research in the field of peripheral nerve regeneration. 
(Neumann & Woolf, 1999) The reasoning for this practice is that peripheral nerve tissue 
undergoes a repair program following injury, during which Schwann cells 
transdifferentiate to a repair phenotype, growth factors such as Glial-Derived 
6 
Neurotrophic Factor (GDNF) are secreted, and infiltrating macrophages release pro-
regenerative cytokines; all in a coordinated fashion which promotes functional 
regeneration of the injured nerve. (Cattin & Lloyd, 2016)  Figure 1.2 summarizes this 
process. The clinical trial researchers hypothesize that by pre-lesioning the nerve tissue 
before grafting they will induce this repair program and create a pro-regenerative tissue 
for implantation. The rationale for this approach is further discussed in the following 
section. 
Peripheral Nerve Grafts to the Central Nervous System 
Peripheral nervous system (PNS) axons are capable of functionally regenerating, 
while central nervous system (CNS) axons cannot (Cajal, 1928). The stark dichotomy 
between PNS and CNS regenerative potential suggests an approach to develop 
therapeutics for PD and other neurodegenerative diseases: make use of the regenerative 
properties of PNS to slow or reverse the progression of the disease by providing the 
existing neurons in the CNS with increased ability to regenerate their projections. 
The capability of peripheral nerves to regenerate, and to support PNS repair, is 
already in use in medical applications. Some microsurgical techniques use peripheral 
nerve scaffolds to bridge large gaps in damaged nerve, improving motor and sensory 
recovery after injury (for review see (Pabari, Yang, Seifalian, & Mosahebi, 2010)). Other 
research focuses on creating synthetic extracellular matrix scaffolds for the same 
purpose, however these artificial scaffolds are far less effective than autologous 
peripheral nerve for facilitating regeneration of nerve tissue and restoring function (for 
7 
review see (Gu, Ding, Yang, & Liu, 2011). This is the first of several pieces of evidence 
discussed that the regenerative properties of peripheral nerve are derived from the 
interaction of multiple tissue components. 
The ability of extracellular matrix to promote axonal regeneration is not seen in 
the CNS. Research has demonstrated the opposite effect: factors such as Nogo and MAG 
in the CNS extracellular matrix regulate and limit axonal growth (Yiu & He, 2006). Thus, a 
axonal growth-inhibiting extracellular matrix distinguishes the CNS from the PNS. 
However, CNS neurons have been shown to be capable of growing through peripheral 
nerve tissue (P. M. Richardson, McGuinness, & Aguayo, 1980). Seminal work from 
Richardson, David, and Aguayo demonstrated that peripheral nerve bridges grafted onto 
the spinal cord and brainstem cause CNS axons to grow into and through the entire length 
of the nerve. It was this finding that led to the first attempts to use PNS tissue to treat 
CNS disorders. Demonstration of spinal cord axon growth into peripheral nerve grafts 
drew much attention for its potential to treat spinal cord injury. The goal of such 
experiments was to bridge injured areas of the spinal cord and re-establish connections 
with distal neurons, restoring motor and sensory function below the lesion. Such 
applications were found to be infeasible when it was demonstrated that spinal cord 
neurons did not grow much beyond the peripheral nerve graft (David & Aguayo, 1981), 
and that functional recovery was unsatisfactory (P. M. Richardson, McGuinness, & 
Aguayo, 1982). More studies examining the use of peripheral nerve are discussed in the 
following section. 
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One prominent difference between PNS and CNS tissue is the presence of 
Schwann cells (SCs) within peripheral nerves. These cells provide mechanical protection 
and electrical insulation to the axons associated with them. SCs also provide trophic 
support for existing axonal populations and facilitate the regeneration of a peripheral 
nerve after injury via the release of soluble neurotrophic factors (Jessen, Mirsky, & Lloyd, 
2015). In response to nerve injury, SCs change their phenotype from a myelinating form 
to a regenerative form (Jessen & Mirsky, 2016; Kidd, Ohno, & Trapp, 2013). Regenerative 
SCs in cutaneous sensory nerve, for example, release soluble growth factors such as nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), insulin-like growth factor-
1 (IGF-1), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), 
neurotrophin-3 (NT-3), and glial cell line-derived neurotrophic factor (GDNF) (Bunge, 
1994; Henderson et al., 1994; Hoke et al., 2006; Park & Hoke, 2014). In doing so the SCs 
of the distal end of an injured peripheral nerve guide new axonal growth from the 
proximal nerve ending (Fu & Gordon, 1997). 
The conversion of SCs from a myelinating phenotype to a repair phenotype is 
controlled by the transcription factor c-Jun. c-Jun induces the activation of genes involved 
in promoting repair (Arthur-Farraj et al., 2012). Trans-differentiation of Schwann cells 
consists of autophagy of myelin (Jung et al., 2011), inhibition of myelin-related gene 
expression (reviewed in (C. J. Chen et al., 2007; Jessen & Mirsky, 2008)), and expression 
of markers for immature Schwann cells such as GFAP and p75 (C. J. Chen et al., 2007; 
Jessen & Mirsky, 2008). In addition to these changes analogous to phenotypic reversion, 
repair Schwann cells also exhibit a phenotype unique from both immature SCs and 
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uninjured myelinating Schwann cells (Arthur-Farraj et al., 2012). Markers that distinguish 
repair Schwann cells include growth factors such as GDNF and Artemin, which promote 
axonal growth and survival of peripheral nerves. (Arthur-Farraj et al., 2012; Fontana et 
al., 2012; Jessen & Arthur-Farraj, 2019). 
There is also evidence to suggest that factors produced by regenerative Schwann 
cells also promote growth of CNS axons. Peripheral nerve grafts lacking SCs are not as 
effective in promoting CNS axon growth as nerve grafts with viable SCs (Smith & 
Stevenson, 1988). Addition of many of the individual growth factors released from SXs 
(GDNF, BDNF, NGF, NT-3, and VEGF) have been shown to promote CNS neuron survival, 
for example NGF (Kromer 1987). Direct trophic factor delivery has been demonstrated to 
be therapeutic in animal models of disease such as Alzheimer’s disease (Tuszynski, U, 
Amaral, & Gage, 1990) and Parkinson’s disease (Gash et al., 1996). Direct delivery of 
trophic factors to the CNS has also been evaluated for treatment of these disease is 
humans, with some degree of success (S. S. Gill et al., 2003; Lang et al., 2006; Slevin et al., 
2005; Tuszynski et al., 2005; A. Whone et al., 2019). These findings demonstrate a less 
explored application of peripheral nerve grafts to the CNS: supplying trophic factors. 
Peripheral nerve cells engineered to overexpress growth factors have the potential to 
serve as living trophic factor delivery systems in a new generation of CNS disorder 
therapeutics. However, details about which specific growth factors are effective in which 
neuronal populations, what dose of growth factors is effective, the logistics of growth 
factor delivery, and coordination with other pro-repair processes have not yet been fully 
explored in the scientific literature. The staggering complexity of the growth factor 
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activity response of peripheral nerve to injury is illustrated by the transcriptomic changes 
after injury described in Chapter Two of this dissertation. Thus there is an elegant appeal 
to using pre-existing autologous peripheral nerve tissue which has the demonstrated 
capacity to promote nervous system repair. 
Trophic factors working in concert with the extracellular matrix, immune cells, and 
other repair SC properties are the pro-regenerative features that led this clinical trial to 
revisit peripheral nerve as a potential disease-modifying therapy for PD. The following 
sections will discuss previous pre-clinical and clinical studies investigating the use of 
peripheral nerve grafts or peripheral nerve cells for grafts to the CNS. 
Pre-Clinical Studies of Peripheral Nerve Grafts to the CNS 
A discussion of peripheral nerve grafting to the CNS would be incomplete 
without acknowledging the work of Richardson, Issa, David, Benfey, and Aguayo. These 
researchers laid the foundation of modern investigations into the ability of PN tissue to 
stimulate CNS axon growth through their multiple animal studies (Albert Aguayo, David, 
Richardson, & Bray, 1982; AJ Aguayo, Vidal‐Sanz, Villegas‐Perez, & Bray, 1987; Albert J 
Aguayo, Benfey, & David, 1983; A. J. Aguayo, Björklund, Stenevi, & Carlstedt, 1984; 
Benfey & Aguayo, 1982; David & Aguayo, 1981, 1985; P. Richardson & Issa, 1984; P. 
Richardson, Issa, & Shemie, 1982). One study particularly relevant to this work is when 
Benfey and Aguayo (Benfey & Aguayo, 1982) showed that basal ganglia neurons grow 
into peripheral nerve, with axons from the striatum showing the most largest number of 
projections into the graft. Another foundational paper showed that fetal mesencephalic 
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dopamine implanted in the CNS and connected to the striatum of a 6-OH-dopamine-
lesioned rat with a peripheral nerve bridge led to the growth of fetal mesencephalic 
dopamine neurons into the striatum. This approach combines two themes of research 
into PN grafting to the CNS: using peripheral nerve as a bridge and replacing specific 
neuronal populations lost in human neurodegenerative disease. 
A previous preclinical study highly relevant to the human DBS+ procedure is 
when Watts and colleagues (Ray L Watts, Mandir, & Bakay, 1995) implanted co-grafts of 
adrenal medulla and sural nerve tissue into the striatum in a MPTP-lesioned macaque 
model of parkinsonism. These implanted animals showed a favorable safety and 
feasibility of the procedure as well as improved motor performance versus controls. This 
study was a continuation of previous research investigating adrenal medulla tissue 
grafts, which contain catecholaminergic chromaffin cells, for the treatment of PD. 
Peripheral nerve was added to this grafting approach in the hopes of improving the 
chromaffin cell survival and efficacy. The continuation of this line of research in humans 
is discussed in the following section. 
Other studies have previously studied the use of isolated peripheral nerve cells 
as grafts to the CNS. Guest and colleagues (Bastidas et al., 2017; Guest, Rao, Olson, 
Bunge, & Bunge, 1997) implanted purified and expanded human SCs with or without a 
solid polymer guidance channels into athymic nude rats given methylprednisolone with 
a T9-T10 spinal cord resection. This study observed that the grafts without channels 
showed more myelinated axons and larger cross-sectional area with growth of 
propriospinal neurons 2.6 mm beyond the grafts. A small increase in motor function was 
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observed in the grafted animals without caps on the channels. This study is also 
particularly relevant due to its use of athymic nude rats, the model organism used in this 
dissertation work and discussed in Chapter Three. 
A later study (Kohama et al., 2001) demonstrated that cultured human SCs 
implanted into the demyelinated spinal cord of Wistar rats immunosuppressed with 
cyclosporine A improved the conduction velocity of the demyelinated rat spinal cord. 
Similarly, Bastides and colleagues (Bastidas et al., 2017; Guest et al., 1997) showed the 
survival, repair properties, and lack of tumorgenicity of cultured human SCs implanted 
into the contused spinal cord of athymic nude rats. The described lack of tumorgenicity, 
or the formation of tumors from the peripheral nerve cells, is supportive of the safety of 
using grafts containing peripheral nerve cells. 
Clinical Trials of Peripheral Nerve Grafts to the CNS 
The history of grafting peripheral nerve tissue to the CNS in humans for the 
treatment of neurodegenerative disease is limited. Adrenal medulla tissue plus peripheral 
nerve grafted to the striatum (R. L. Watts et al., 1997) established the safety of peripheral 
nerve grafts for the treatment of PD. However, follow-up at two years showed no 
significant motor improvements. This study differed in three significant ways from the 
current clinical trial discussed in this dissertation: the grafts were not implanted in 
combination with DBS, the grafts contained adrenal medulla tissue, and the grafts were 
targeted to the striatum 
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A second study of note is the use of PN grafts serving as tissue bridges plus bulbar 
olfactory ensheathing cells showed some efficacy in inducing functional regeneration in 
one patient with a transected spinal cord. (Tabakow et al., 2014). This work highlights one 
the most compelling possibilities of the use of peripheral nerve tissue grafting to the CNS: 
serving as a bridge to guide regenerating CNS axons across blocking lesions. The addition 
of bulbar olfactory ensheathing cells, and promising results, perhaps indicates the 
untapped potential of peripheral nerve as a therapeutic for spinal cord injury. 
Expanded discussion of peripheral nerve grafts to the CNS can be found in the 
upcoming review article “Peripheral Nerve Tissue Grafting for Repair of the CNS in Trauma 
and Degenerative Disease” (El Seblani and Welleford et al., in preparation). 
Conclusions 
The primary research aim of this clinical trial evaluate whether PN tissue grafts to 
the brain can reduce neuronal loss and slow the clinical progression of neurodegenerative 
diseases like Parkinson’s disease. There are several unanswered questions about this 
approach, and its implementation in these clinical trials, that this dissertation project 
aimed to address. What is the exact cellular and molecular composition of the PN grafts 
used in these trials? Does the conditioning injury approach induce the predicted changes 
to nerve phenotype? In order to assess these questions, the second dissertation chapter 
details analysis of the peripheral nerve tissue used in the above clinical trials with respect 
to tissue composition and gene expression, both of injury-naive human peripheral nerve 
as well as the post-conditioning injury tissue used in the grafting procedure. Histology is 
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used to survey the structure of the peripheral nerve grafts used in the clinical trials. RNA-
seq analysis of sural nerve tissue pre- and post-conditioning injury show significant 
changes in gene expression corresponding with transdifferentiation of Schwann cells from 
a myelinating to a repair phenotype, release of growth factors, activation of macrophages 
and other immune cells, and an increase in anti-apoptotic and neuroprotective gene 
transcripts. These results reveal in vivo gene expression changes involved in the human 
peripheral nerve injury repair process, which has relevance beyond this clinical trial to the 
fields of Schwann cell biology and peripheral nerve repair. 
Next, this dissertation project aimed to answer the question: how does the graft 
tissue respond after implantation in the brain? And does injury-naïve PN tissue differ from 
injury-conditioned tissue in this response?  The third chapter of this dissertation details 
the development of an animal model of the grafting procedure aimed to answer these 
questions. This animal model, termed Neuro-Avatars, features human peripheral nerve 
tissue implanted into athymic nude rats. Survival and infiltration of human graft cells into 
the host brain were shown using immunohistochemistry of Human Nuclear Antigen. The 
logistics, implementation, and findings of these experiments are discussed. 
Lastly, this dissertation addresses the question: how does the neurobiology of the 
graft correlate with clinical outcomes? The fourth chapter of my dissertation includes a 
published report of the safety and feasibility of the ongoing clinical trials with further 
details about the human surgical procedure. To connect the results of these laboratory 
studies to the clinical trial, fifth chapter compares the severity of motor symptoms before 
surgery to one year post-surgery in patients who received the analyzed graft tissue. Motor 
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symptom severity was assessed using the Unified Parkinson’s Disease Rating Scale Part 
III. Finally, the fifth chapter discusses correlates between the laboratory and clinical data 
collected by these clinical trial as well as the implications of this dissertation work for 
future clinical trial decisions. 
This dissertation project aims first and foremost to be translational: to connect 
basic science and clinical research in a meaningful way. Taken together, the findings 
discussed in this dissertation answer many questions that arose in the course of clinical 
trials investigating peripheral nerve grafts to the brain for the treatment of Parkinson’s 
disease. This work also identifies new basic science and clinical research questions that 
can be addressed by future translational research. In summary, this dissertation advances 
the translational science cycle by using clinical trial findings and samples to answer basic 
science questions that will in turn guide future clinical trial design. 
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Chapter 1 Figures 
 
Figure 1.1: Implantation of autologous peripheral nerve graft in the substantia nigra of a 
human subject with Parkinson’s disease.  
During Stage I of DBS surgery a conditioning injury is introduced to the sensory sural nerve 
to activate the repair phenotype of the Schwann cells. The distal segment of the 
conditioned sural nerve, which contains the repair SCs, is harvested after two weeks 
during Stage II of DBS surgery. The epineurium is removed, the fascicles are stripped and 
sectioned into 5 segments and loaded into a custom-made graft cannula. The grafts are 
stereotaxically deployed in the degenerating substantia nigra. 
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Figure 1.2: Schematic of the Repair Schwann Cell 
After a nerve injury, distal SCs shed myelin, lose SC differentiation markers, re-express 
precursors markers, alter their morphology, and migrate within regenerating tracks 
(Büngner bands). These tracks guide the regenerating axons back to their functional 
targets. SCs crosstalk with the macrophages and they interact with the released cytokines 
to activate different inflammatory pathways. The axonal debris and the myelin are 
cleared up by both the repair SCs and the macrophages to promote the regeneration of 
the new axons. The pro-myelinating genes are downregulated by c-Jun, Sox-2, Pax-3, Id2, 
and Egr-1/3 transcription factors. Repair SCs release various neurotrophic factors 
including NGF, BDNF, NT-3, NT-4/5, CNTF, trkB, trkA, GDNF, and Neuregulin. These factors 
induce neurite growth locally and transported retrograde towards the perikaryon to 
upregulate the anti-apoptotic pathways and enhance the injured neuron. 
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Chapter Two: RNAseq Characterization of Peripheral Nerve Tissue 
RNAseq Analysis of Human Sural Nerve Fascicles Pre- and Post-Injury: Evidence for Trans-
differentiation of Human Peripheral Nerve2 
Introduction 
It has long been known that peripheral nerve tissue is capable of functional repair 
after injury (Cajal, 1928). In contrast to central nervous system (CNS) axons, the axons of 
the peripheral nervous system (PNS) are capable of regenerating after injury (Brushart, 
2011) and re-establishing functional connections with their distal target (Sebille & 
Bondoux-Jahan, 1980). This regeneration is enabled by the interaction between axons, 
the nerve extracellular matrix, immune cells such as macrophages, and Schwann cells 
(Oldfors, 1980; Pellegrino, Politis, Ritchie, & Spencer, 1986). These nerve components 
individually contribute to peripheral nerve repair and interact with each other to further 
support functional regeneration (Jessen & Arthur-Farraj, 2019). 
Following peripheral nerve injury, axons distal to the lesion undergo a process 
known as Wallerian degeneration. These distal portions of the axon undergo a controlled 
process of myelin, axon membrane, and axon cytoskeletal breakdown followed by 
clearance by Schwann cells and macrophages (Gaudet, Popovich, & Ramer, 2011). Under 
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favorable conditions the proximal segment of the neuron can sprout new processes that 
re-associate with Schwann cells and regenerate through the remaining extracellular 
matrix of the distal nerve. In this way, the regenerating peripheral nerve can re-establish 
communication with its distal target and restore some degree of function. 
Schwann cells are the primary supporting cells (glia) of the PNS and normally 
surround PNS axons and insulate them with myelin. In response to peripheral nerve injury 
Schwann cells change their phenotype from a myelinating form to a regenerative, or 
trans-differentiated form (Kidd et al., 2013). They shed their myelin, become mobile, and 
secrete growth factors and other signaling molecules to promote clearance of myelin 
debris and axonal regrowth (Jessen & Mirsky, 2016). For example, Schwann cells in injured 
cutaneous sensory nerve release soluble growth factors such as nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), 
hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), 
neurotrophin-3 (NT-3), and glial cell line-derived neurotrophic factor (GDNF) (Hoke et al., 
2006). These growth factors play a role in guiding the distal end of an injured peripheral 
nerve and guide new axonal growth from the proximal nerve ending (Fu & Gordon, 1997). 
The genes and gene products involved in successful recovery of peripheral nerve 
after injury are of particular interest in the basic science fields of neural protection, 
regeneration, and repair. Promoting successful regeneration in the central nervous 
system is the subject of clinical and translational research in neurodegenerative diseases, 
traumatic brain injury, stroke, epilepsy, and others. Understanding the process of 
peripheral nerve repair requires consideration of all peripheral nerve components as well 
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as the interaction between these components. In addition, the most clinically relevant 
research must take place in humans.  
Whole-transcriptome responses to peripheral nerve injury can now be feasibly 
studied using RNA-seq. RNA-seq combines molecular biology approaches for RNA 
amplification with bioinformatics approaches for measuring and validating large RNA 
sequencing datasets. This technique allows for quantitative measurements of thousands 
of gene transcripts using small (10-30 mg or less) quantities of tissue. For review of the 
many applications of RNAseq see (Han, Gao, Muegge, Zhang, & Zhou, 2015). 
This study was conducted in conjunction with an ongoing clinical trial 
(clinicaltrials.gov: NCT#02369003), which involves the surgical collection of human 
peripheral nerve from patients with Parkinson’s disease for use in an experimental nerve 
graft surgery in combination with Deep Brain Stimulation (DBS) (van Horne et al., 2018). 
The goal of this ongoing clinical trial is to slow the progression of motor symptoms of 
Parkinson’s disease (PD) by providing a source of neuroprotective and/or pro-
regenerative factors to the basal ganglia, the brain area causing the prominent motor 
deficits seen in PD. Peripheral nerve tissue was chosen because it has been successfully 
transplanted to the CNS in both animal models (Albert Aguayo et al., 1982) and humans 
(Tabakow et al., 2014; Ray L Watts et al., 1995). In addition, peripheral nerve tissue has 
been shown to release neurotrophic factors such as GDNF, which has been evaluated for 
use as a PD therapeutic and the nerve can be collected intraoperatively from the same 
patient. This surgery, performed as a part of a Phase I clinical trial, involves the collection 
of two samples of peripheral nerve: one initial sample that is cut from the participant’s 
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sural nerve, and a second sample taken two weeks later from the distal end of the same 
nerve for implantation into the substantia nigra (van Horne et al., 2018). The samples 
collected are surgically isolated fascicles of peripheral nerve after the epineurium has 
been removed. This two-stage approach corresponds with the two stages of DBS surgery 
and was designed with the objective of inducing pro-regenerative changes in the 
peripheral nerve following injury as described in the literature (Cattin & Lloyd, 2016; Fu 
& Gordon, 1997). To evaluate whether this two-stage approach is successful in inducing 
pro-regenerative changes in peripheral nerve tissue we used a transcriptomic approach 
to characterize both sets of tissue. This surgical protocol enables the analysis of human 
peripheral nerve tissue response to transection injury from the same human subject, 
which is to the best of our knowledge the first study of this type. The results provide 
insights into changes in human peripheral nerve tissue in response to injury, which may 
guide therapies and molecular target development for repair of both the peripheral and 
central nervous system. 
Methods 
Subjects 
Six participants in the clinical trial, which met DBS criteria for the DBS therapy for PD (2 
female, 4 male) aged 63.8 + 6.9 SD years (range 53-70 years), were selected for RNASeq 
analysis. The study was approved by the University of Kentucky institutional review board, 
and informed consent was obtained from all study participants.  
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Tissue collection 
Human sural nerve samples were collected during DBS surgeries. DBS at our 
institution is carried out in two stages: Stage I is followed by Stage II two weeks later. (van 
Horne et al., 2017) For the Stage I tissue collection, the surgeon made a transverse incision 
through the skin of the lateral ankle, 2 cm superior to the lateral malleolus. The surgeon 
then identified the neurovascular bundle containing the sural nerve and associated artery 
and vein. The sural nerve was then separated from the bundle using blunt dissection. Next 
two black silk sutures were tied around the nerve roughly 1 cm apart to mark the nerve. 
The section of the sural nerve between these sutures was then cut, a piece removed, and 
the surgical area sutured closed. 
The removed section of nerve was then stripped of its epineurium using 
microsurgical dissection in sterile saline. Individual fascicles of nerve fibers were 
separated using jeweler’s forceps and the perineurium was discarded. These fascicles 
were placed in conical micro-centrifuge tubes and snap-frozen on dry ice before long-
term storage at -80°C until assayed. For Stage II tissue collection, the surgical area from 
Stage I was reopened at the original incision. The surgeon located the suture markers on 
the sural nerve and removed a new piece of tissue from the distal stump of the nerve. 
This tissue was kept on sterile saline ice before implantation. Tissue was prepared for 
study intervention as in (van Horne et al., 2017).  Once the study intervention was 
completed, the remaining fascicles were placed in conical micro-centrifuge tubes, snap-
frozen on dry ice, and stored at -80°C until assayed.  
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Preparation for Histology 
Surgical tissue preparation was performed as above to the point of fascicle 
isolation. Fascicles were then placed in 4% paraformaldehyde solution. The tissue was 
then embedded in paraffin blocks for histological evaluation. 
Histology 
Surgical tissue preparation was performed as above to the point of fascicle 
isolation. Fascicles were then placed in 4% paraformaldehyde solution. The tissue was 
then embedded in paraffin blocks for histological evaluation. (Raimondo et al., 2009) 
RNA Extraction 
 RNA isolation was performed by homogenizing sural nerve fascicles in 1ml of TRI 
Reagent Solution (ThermoFisher AM9738) using a Fisher Scientific Power Gen 35 
homogenizer with a microtip homogenizing probe. The homogenized lysate was 
transferred to a pre-pelleted 5Prime Phase Lock Gel – Heavy 2 mL tube (ThermoFisher 
NC1093153) and incubated at room temperature for 5 minutes. 200ul of chloroform was 
added and the tube was shaken vigorously by hand 15 seconds. Phase separation was 
performed by microcentrifugation at 12,000 x g for 10 minutes. The RNA containing 
aqueous phase was taken from the top of the Phase Lock Gel layer and transferred to a 
1.7 mL microfuge tube. RNA was precipitated by adding 0.5 ml isopropyl alcohol, mixed 
by repeated inversion and incubated at room temperature for 10 minutes. RNA was 
pelleted by microcentrifugation at 12,000 x g for 10 minutes at 4°C. RNA pellet was 
washed two times with 80% ethanol using a 7,500 x g microcentrifugation for 5 minutes 
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at 4°C to pellet RNA between washes. RNA pellets were air dried 5-10 minutes at room 
temperature and resuspended in 25ul of nuclease free water. RNA purity was assessed by 
OD260/OD280 ratio calculation using a ThermoFisher NanoDrop 1000. RNA Integrity was 
assessed by Agilent Bioanalyzer 2100 using the Eukaryotic Total RNA Nano assay.  
RNA-seq Analysis of Sural Nerve Fascicles 
RNA-Sequencing was performed at a strand specific 100 cycle paired-end 
resolution, in an illumina HiSeq 2500 sequencing machine (Illumina, San Diego, CA). In a 
repeated measure design, mRNA from six individual samples were sequenced before and 
after surgery resulting in 12 samples in total. The 12 samples were multiplexed in two 
lanes of a flow-cell, resulting between 25 and 34 million reads per sample. The read 
quality was assessed using the FastQC software. (Andrews, 2010) On average, the per 
sequence quality score measured in the Phred quality scale was above 30 for all the 
samples. The reads were mapped to the human genome (GRCh38) using the STAR 
software, version 2.3.1z. (Dobin et al., 2013) On average, 96.4% of the sequenced reads 
mapped to the genome, resulting between 24.3 and 32.8 million mapped reads per 
sample, of which on average 89% were uniquely mapped reads. Transcript abundance 
estimates were calculated using HTSeq (version 0.6.1). (Anders, Pyl, & Huber, 2015) 
Expression normalization and differential gene expression calculations were performed 
in edgeR (release 2.14) (Robinson, McCarthy, & Smyth, 2010) to identify statistically 
significant differentially expressed genes. A paired sample design was used in edgeR, 
which employs a negative binomial generalized linear model (NB-GLM) for statistical 
calculations. The edgeR package implements advanced empirical Bayes methods to 
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estimate gene-specific biological variation under minimal levels of biological replication. 
The RNA composition in each sample was normalized in edgeR using the trimmed mean 
of M-values (TMM) method. The significance p-values were adjusted for multiple 
hypotheses testing by the Benjamini and Hochberg method (Benjamini & Hochberg, 1995) 
as modified by Storey (Storey & Tibshirani, 2003), providing a false discovery rate q value 
for each differentially expressed gene. Genes with an absolute fold difference ≥ 2 and q ≤ 
0.05 were considered statistically significant. 
Analysis 
RNAseq data were organized in a Microsoft Excel table for subsequent analyses. 
The fold changes between Stage 1 and Stage 2 were converted to log base 2 for down-
stream analysis. The normalized read counts (counts per million- CPM) were used when 
calculating correlations between samples and generating heat-maps.  
Correlation matrices and heat maps, as well as volcano plots, were generated in 
Excel. Functional overrepresentation analysis on the Gene Ontology set of pathway 
annotations (Harris et al., 2004) was performed using DAVID pathway analysis. (Huang 
da, Sherman, & Lempicki, 2009) 
AmiGO Gene Ontology annotations (http://www.geneontology.org/) for 
pathways of interest were cross-referenced with significantly differentially expressed 
genes. The gene ontologies visualized in heat maps were selected based on their 
relevance to peripheral nerve repair. Statistical criteria of q <= 0.05 and |FC|>= 2 were 
selected, yielding 3,641 differentially expressed genes in this analysis. Heat maps of the 
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qualifying genes were generated using JMP Pro 13 (SAS). Hierarchical clustering was 
performed using Ward’s method in JMP. 
Results 
Tissue Samples 
 The mass and freezing delay time (time from when the nerve was removed from 
participant to when it was snap-frozen in dry ice) were calculated for tissue collected for 
RNAseq from Stage I (Table 2.1) and Stage II (Table 2.2). Freezing Time Delay was nearly 
three times longer at Stage II (59 ± 25 min; Mean ± SD) compared to Stage I (18 ± 5 min). 
The peripheral nerve tissue in Stage II was successfully grafted into the participant before 
the companion, excess tissue was frozen. 
Histology 
The morphology of the surgical tissue samples was assessed using standard H&E 
histology and MCOLL staining, which differentiates myelin, collagen fibers, and cells in 
peripheral nerve (see Figure 2.1). The tissue morphology was consistent with peripheral 
nerve, confirming that the tissue harvested in the surgery and used in grafts was 
peripheral nerve fascicles. Myelinated fibers, extracellular matrix, and cells were all visible 
in both Stage I and Stage II tissue. Of note, Stage II samples showed increased numbers 
of cell nuclei compared to Stage I, suggesting infiltration and proliferation of immune cells 
as described in the literature (Cattin & Lloyd, 2016). These findings are supported by 
increased cytokines and immune cell markers as described below. Tissue analyzed by 
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histology was collected from study participants using the procedure described in the 
methods section, but tissue from these participants was not assessed with RNAseq. 
Correlation Matrix and Volcano Plot 
 When we correlated the gene profiles of individual participants’ samples with 
respect to nerve injury status (Stage I or Stage II), we found high correlation between 
participant’s gene profiles within the acute injured status samples (Stage I) and within the 
regenerative status samples (Stage II), but not across Stage I and Stage II status (Figure 
2A). The analysis of the samples showed consistent and robust changes in RNA levels 
among all 6 participants in response to the nerve cut injury. These results provide 
evidence that the nerve regeneration was successful in inducing phenotypic changes in 
the peripheral nerve tissue used in the grafting procedure. A consistent gene profile in 
Stage II tissue also allows for greater confidence in interpreting the individual participant 
responses to the grafting procedure. 
 The Volcano plot (Figure 2B) estimates the most meaningful changes in the gene 
transcriptome, between Stage I and Stage II that exceeded a  cutoff of q ≤ 0.0003; and   
fold change |FC| >= 4. Of those significantly differentially expressed genes, 693 gene 
transcripts (orange) were increased and 576 gene transcripts were decreased (blue). This 
analysis demonstrates that even with a very conservative criteria, there are hundreds of 
differentially expressed genes between the Stage I and Stage II tissue samples 
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DAVID Pathway Analysis 
 DAVID is an online software tool that groups genes based on their functional 
similarity. Given a list of significantly differentially expressed genes, DAVID uses a fuzzy 
clustering algorithm, that uses information in its knowledge base on genes and their 
functional associations, to group genes that are together, statistically significant in their 
association to a set of common functional categories. (Huang da et al., 2009)      
DAVID analysis revealed that the majority of the most significantly increased 
pathways in the injury-conditioned samples (Table 3) were related to cell cycle, cell 
proliferation, and immune cell function. The majority of the most significantly down-
regulated pathways (Table 4) were related to synaptic structure and neuron function. 
These transcriptome trends match the phenotype of peripheral nerve responding to 
injury: immune cell infiltration plus cell proliferation with Wallerian degeneration of 
axons. (Arthur-Farraj et al., 2012; Arthur-Farraj et al., 2017; Cattin & Lloyd, 2016) 
Heat Maps 
 Heat maps were generated from gene ontology terms of interest to this study 
drawing from the peripheral nerve regeneration literature (Arthur-Farraj et al., 2012; 
Arthur-Farraj et al., 2017; Cattin et al., 2015; Cattin & Lloyd, 2016) and pathways of 
interest to the research teams. 
Growth Factors  
 Figure 2.3 shows all significantly differentially expressed (q< 0.05, |FC|>2) gene 
transcripts annotated with the Gene Ontology (GO) term “Growth factor Activity” 
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(GO:0008083), indicating that there is literature evidence of these genes being involved 
in “The function that stimulates a cell to grow or proliferate.” Out of 166 unique genes 
with this ontology, 43 (25.9%) of these genes were significantly differentially expressed 
between Stage I and Stage II. 26 genes were more abundant and 17 genes were less 
abundant in Stage II samples than Stage I. Of particular note were the neurotropic factor 
genes for GDNF, FGF, and others. These results showed significant increases after injury 
in transcripts of growth factor genes known to promote neuroprotection in the CNS, 
including GDNF. 
Myelination 
Out of 110 unique gene transcripts identified with the GO term “Myelination” 
(GO:0042552), “the process in which myelin sheaths are formed and maintained around 
neurons,” 48 (43.6%) were significantly differentially expressed (7 genes were more 
abundant and 41 genes less abundant in Stage II samples than Stage I samples, Figure 
2.4).  These results show significant decreases in myelination-related gene transcripts 
consistent with loss of myelinating-phenotype Schwann Cells. 
Schwann Cell De-Differentiation 
Using the GO term “Epithelial-Mesenchymal Transition” (GO:0001837), “a 
transition where an epithelial cell loses apical/basolateral polarity, severs intercellular 
adhesive junctions, degrades basement membrane components and becomes a 
migratory mesenchymal cell,” yielded 130 unique genes. Of these, 29 (22.3%) were 
significantly differentially expressed (24 genes were more abundant and 5 genes less 
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abundant in Stage II samples than Stage I samples, Figure 2.5).  Likewise, the GO term 
“Schwann Cell Differentiation” (GO:0014037), “the process in which a relatively 
unspecialized cell acquires the specialized features of a Schwann cell” identified, 36 
unique genes. Of these, 15  (41.7%) were significantly differentially expressed, with only 
1 gene being more abundant while the other 14 genes were less abundant in Stage II 
samples than Stage I samples (Figure 2.5). These results indicate a loss of markers of 
mature (myelinating) Schwann cell phenotype and increase in markers of trans-
differentiation of cells. Taken together, these gene changes are consistent with the trans-
differentiation of Schwann cells following injury from a mature (myelinating) form to a 
repair phenotype. 
Neuroprotection 
Figure 2.6 shows all significantly differentially expressed gene transcripts 
annotated with the GO term “Negative Regulation of Apoptotic Processes” (GO:0043066) 
or “Negative Regulation of Neuron Death” (GO:1901215).  “Negative Regulation of 
Apoptotic Processes” is defined by “the process in which myelin sheaths are formed and 
maintained around neurons. This ontology yielded 916 unique genes, of which, 128 
(14.0%) were significantly differentially expressed (all 128 genes were more abundant in 
Stage II samples than in Stage I samples). Meanwhile, for Negative Regulation of Neuron 
Death, “any process that stops, prevents or reduces the frequency, rate or extent of 
neuron death,” we found 67 genes out of 206 (32.5%) were significantly differentially 
expressed (45 genes more abundant and 22 genes less abundant in Stage II samples than 
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in Stage I samples). These gene changes indicate significant increases in transcripts of 
genes related to the reduction of neuron death. 
Discussion 
A major finding from the current study is that the RNAseq data support the 
feasibility and reproducibility of the time-delayed approach for producing trans-
differentiation of the sural nerve tissue into a repair cell phenotype. Histology and 
transcriptome profiles were consistent with peripheral nerve that has undergone injury 
response (Arthur-Farraj et al., 2017; Weiss et al., 2016; Yi et al., 2015). Furthermore, the 
correlation matrix visualizes the consistent RNA levels between participants as a result of 
the pre-lesioning approach we call Stage I (van Horne et al., 2017; van Horne et al., 2018). 
The participants who contributed tissue for this study had all been diagnosed with 
idiopathic PD for over 5 years and ranged in age from 53 to 70, with Movement Disorders 
Society- Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III motor function 
scores, while having stopped PD medication, that ranged from 22-75 points (the scale 
ranges from 0 [normal] to 132 points [most affected]). It is possible that the disease 
processes of this neurodegenerative disorder had some effect on peripheral nerve gene 
expression and its injury response. For example, recent evidence has identified that 
phosphorylated forms of alpha-synuclein are found in some peripheral nerves of 
Parkinson’s patients. (Donadio et al., 2014; Doppler et al., 2014; Zhang et al., 2019) In 
other participants of the clinical trial (not included here), who have had a history of 
neuropathy, we have used clinical nerve conduction velocity tests to assess the sural 
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nerve before grafting. None of those participants showed remarkable decrement in nerve 
conduction velocity (data not shown). A future study comparing baseline levels of RNA in 
patients with Parkinson’s versus age-matched healthy controls could help determine 
potential baseline differences. These results are also valuable from a clinical trial 
perspective as they provide evidence for homogeneity of the treatment being applied in 
the PD population. The transcriptome of the nerve tissue is similar between all 
participants even though they range in age and PD severity and also in other co-
morbidities that might affect the trans-differentiation process. In addition, based on the 
high degree of correlation within the samples from Stage I and from Stage II, shown in the 
correlation matrix results, the results support that the surgical procedure and sample 
collection protocols, in spite of the variability involved in collecting the tissue, e.g. the 
Freezing Time Delay, led to consistent results from the tissue samples. These benchmarks 
could serve as potential quality-assurance metric if this technique were to be adopted as 
part of a multicenter trial. 
 Another major finding of the study is that it provides RNAseq quantification of 
gene transcripts in peripheral nerve tissue being grafted into the brain. These data answer 
pressing questions from the clinical trial as to the phenotype of the nerve tissue used in 
the grafting procedure (van Horne et al., 2018). There is now evidence for the expression 
of specific growth factors such as GDNF, which is known to be neuroprotective, especially 
to dopaminergic neurons of the substantia nigra (Gash et al., 1996; Grondin et al., 2002; 
Kirik, Georgievska, & Bjorklund, 2004). Given that the target of this grafting trial is the 
substantia nigra, this finding supports the neuroprotective potential of this graft tissue.  
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Along these lines, the freezing time delay differences between Stage I and Stage II 
is one of the variabilities within the design of our study. This was inherent to the trial 
design where the focus was to optimize the grafting procedure and the availability of 
tissue to be grafted. So while in Stage I the tissue was processed to isolate the fascicles 
immediately after extraction, in Stage II, the tissue was extracted, placed on saline ice, 
the sural nerve incision was closed, the target areas were prepared, and the tissue was 
grafted. We recognize this delay represents a difference in the freezing time delay 
between the stages; however, because the fascicles that are snap-frozen at Stage II are 
parts of the tissue that was actually implanted, by content and exposure time, we think 
the analysis of this tissue, after the delay, best reflects our “study intervention.” 
This study also highlights gene changes that play a role in the injury response of 
the human peripheral nerve. This analysis of peripheral nerve repair is in the context of a 
full transection injury. Other injury modalities, for example crush injuries, have been 
shown to induce different repair processes than transection injury (Lago & Navarro, 
2006). This should be considered when applying these findings to other injury models. 
Comparing differentially expressed genes between Stage I and Stage II reveals many 
functional pathways involved in the tissue response to injury.  
 Growth factor activity showed multiple differentially expressed genes. One 
increased gene of note is GDNF, which is neuroprotective of dopaminergic neurons and 
has been tried as a therapeutic for Parkinson’s disease (Gash et al., 1996; S. S. Gill et al., 
2003; A. Whone et al., 2019; A. L. Whone et al., 2019). Multiple interleukins were also 
upregulated, which in addition to being cytokines, also play a role in neurogenesis (for 
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review see (Borsini, Zunszain, Thuret, & Pariante, 2015)). The myelination genes showed 
that the most significantly differentially expressed genes of this ontology were decreased 
two weeks after injury. This is consistent with myelin degradation after peripheral nerve 
injury as described in the literature (Gomez-Sanchez et al., 2015). In general the Schwann 
cells showed overall decreased transcripts related to differentiation. This could be 
interpreted as de-differentiation of Schwann cells described in the literature (Arthur-
Farraj et al., 2012). However, this comparison was not straightforward. We expected to 
see that the JUN gene, which codes for the c-Jun transcription factor that regulates 
Schwann cell trans-differentiation, would be increased (Arthur-Farraj et al., 2012). 
However, this gene was not significantly differentially expressed in these samples. We 
currently hypothesize that the time course of JUN transcription did not match with the 
two samples taken two weeks apart, or that post-translational processing of c-Jun has 
more influence on its activity. In fact, the present study is limited in that it only addresses 
the levels of gene transcripts in the fascicles two weeks after the transection. Ideally, 
future studies should strive to investigate both shorter (3 to 7 days) and longer 3-6 weeks 
post injury to understand more about the trans-differentiation process.  
Negative regulation of apoptotic processes describes genes that decrease 
apoptosis, and includes anti-apoptotic properties that are of interest to us for therapeutic 
benefit. The visualization of this ontology were striking: over one hundred genes were 
significantly differentially expressed and all were up-regulated. This suggests that marked 
suppression of apoptosis is occurring in this tissue. Whether these anti-apoptotic 
processes confer neuroprotection after tissue grafting merits study. 
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Human studies of the peripheral nerve transcriptome are few. To our knowledge 
only Weiss and colleagues (Weiss et al., 2016) have performed RNAseq on human 
peripheral nerve fascicles. They studied human peripheral nerve fascicles collected during 
surgeries, ex vivo degenerated nerves (8 days post-lesion), cultured Schwann cells, and 
cultured fibroblasts. Their method of obtaining degenerated nerves differed from ours in 
that our model was degenerated in vivo and collected 14 days post-injury. Studies in 
animal models are more common. Arthur-Farraj (Arthur-Farraj et al., 2017) and 
colleagues reported transcriptome and DNA methylome findings from mouse models. 
They found changes in epithelial-mesenchymal transition, which we also observed. They 
also analyzed non-coding RNA. Yi (Yi et al., 2015) and colleagues studied a rat model of 
sciatic nerve crush injury. Of note: both Arthur-Farraj et al. and Yi et al. performed 
sequencing at multiple time points post-injury. This approach allowed them to show the 
change in differentially expressed pathways over time. 
Our RNAseq analysis limits the genes visualized to those exceeding a fold change 
threshold of |FC|>2 or 4. This is an arbitrary convention meant to refine the results of 
RNAseq to a more “biologically relevant” dataset. However, this convention may exclude 
genes that are in actuality biologically relevant. For example, transcripts of NF2, a marker 
of Schwann Cell proliferation, were statistically significantly increased (p=0.0192). 
However, the average magnitude of increase was less than 2, so it was not included in the 
visualized data. Furthermore, we focused in this paper only on transcripts that were 
differentially expressed between Stage II and Stage I while recognizing that some genes 
could be highly expressed in both stages, but not differentially so. This is one limitation of 
36 
this broad analysis approach, and in the specific case of NF2 levels in this tissue merits 
further study. 
The sural nerve fascicles analyzed included all cells and tissue components within 
the peripheral nerve. It should be noted that the tissue analyzed does not include the 
epineurium of the sural nerve. This was intentional, as it reflects the graft tissue 
composition (fascicles only), which is intended to contain mostly Schwann cells, 
macrophages, and extracellular matrix. This yielded an aggregate of all RNA in the tissue 
from multiple cell types. A future study using single-cell RNA-seq would be able to 
investigate the responses of individual peripheral nerve cells and cell types, which would 
likely be of great value to the field of neural regeneration and repair. Thus, it is possible 
that while we have emphasized the importance of the Schwann cells in the RNAseq data 
and the “repair cell” properties of the tissue that the results cannot at this time be solely 
attributed to changes in Schwann cells. 
 Taken together, the results from this study present whole-tissue transcriptome-
scale data of human peripheral nerve shortly following transection injury versus two 
weeks post-injury from the distal portion of the same injured nerve. The findings of this 
study reveal significant changes in the transcriptome of an injured human peripheral 
nerve after two weeks of repair processes in situ. These results provide data for future 
researchers to analyze and incorporate into their bioinformatics models information 
regarding normal peripheral nerve and its injury response. Such models may provide 
insight into the peripheral nerve repair process and its relevance to basic science research 
into peripheral nerve and Schwann cells as well as clinical and translational research 
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looking to adapt peripheral nerve tissue for use in promoting neuroprotection, neural 
repair, axonal regeneration, or other therapeutic strategies for nervous system disorders. 
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Chapter 2 Tables 
Participant Mass (g) Freezing Time Delay* (min) 
1 0.0205 16 
2 0.0158 28 
3 0.0254 20 
4 0.0256 14 
5 0.0294 14 
6 0.0197 17 
Mean ± SD 0.0227± 0.0049 18 ± 5 
* Freezing Time Delay includes the gross dissection time during which fascicles were 
separated from the whole nerve. 
 
Table 2.1: Stage I Mass and Freezing Time Delay 
Mass and storage information for nerve samples collected during Stage I DBS surgeries. 
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Participant Mass (g) Freezing Time Delay* (min) 
1 0.0354 41 
2 0.0301 108 
3 0.0613 64 
4 0.0363 52 
5 0.0757 39 
6 0.0256 50 
Mean ± SD 0.0441 ± 0.0198 59 ± 25 
* Freezing Time Delay includes the gross dissection time during which fascicles were 
separated from the whole nerve and the time required for fascicle segment grafting into 
participants during Stage II. 
 
Table 2.2: Stage II Mass and Freezing Time Delay 
Mass and storage information for nerve samples collected during Stage I DBS surgeries. 
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Term Upregulated 
Number of gene 
transcripts P Value 
GO:0000278 mitotic cell cycle 83 2.42E-32 
GO:0007067 mitotic nuclear division 57 3.97E-31 
GO:0000819 sister chromatid segregation 41 1.20E-27 
GO:0044770 cell cycle phase transition 49 4.75E-19 
GO:0071103 DNA conformation change 32 1.21E-16 
GO:0002682 regulation of immune system process 62 4.67E-14 
GO:0000228 nuclear chromosome 41 3.38E-13 
GO:0006952 defense response 58 1.11E-11 
GO:1901987 regulation of cell cycle phase transition 29 5.00E-11 
GO:0051303 establishment of chromosome localization 14 2.42E-10 
GO:0006259 DNA metabolic process 46 4.49E-09 
GO:0002366 
leukocyte activation involved in immune 
response 19 6.52E-09 
GO:0042129 regulation of T cell proliferation 16 1.64E-08 
GO:0051321 meiotic cell cycle 17 2.41E-07 
GO:0006342 chromatin silencing 13 5.18E-07 
GO:0033043 regulation of organelle organization 46 5.84E-07 
GO:0032640 tumor necrosis factor production 12 7.16E-07 
GO:0000910 cytokinesis 13 1.42E-06 
GO:0046631 alpha-beta T cell activation 12 2.69E-06 
GO:0001932 regulation of protein phosphorylation 45 3.85E-06 
GO:0006302 double-strand break repair 16 6.15E-06 
GO:0007051 spindle organization 12 1.01E-05 
GO:0050663 cytokine secretion 13 1.54E-05 
GO:0032101 regulation of response to external stimulus 28 2.78E-05 
GO:0032675 regulation of interleukin-6 production 10 2.86E-05 
GO:0019899 enzyme binding 54 3.65E-05 
GO:0060089 molecular transducer activity 35 3.80E-05 
GO:0044774 mitotic DNA integrity checkpoint 11 5.42E-05 
GO:0006270 DNA replication initiation 7 5.53E-05 
GO:0002704 
negative regulation of leukocyte mediated 
immunity 7 6.60E-05 
GO:0032760 
positive regulation of tumor necrosis factor 
production 8 7.62E-05 
GO:0034501 protein localization to kinetochore 5 8.20E-05 
GO:0009897 external side of plasma membrane 14 8.27E-05 
 
Table 2.3: Top Significantly Increased Pathways During Regeneration 
DAVID pathway analysis of RNAseq data showing the pathways of most significantly 
increased gene transcripts. 
41 
  Term Downregulated 
Number of 
gene 
transcripts P Value 
GO:0042391 regulation of membrane potential 17 2.69E-08 
GO:0098590 plasma membrane region 27 4.06E-08 
GO:0050803 regulation of synapse structure or activity 14 8.01E-08 
GO:0050877 neurological system process 22 7.00E-07 
GO:0050808 synapse organization 13 8.20E-07 
GO:0048812 neuron projection morphogenesis 18 4.23E-06 
GO:0030426 growth cone 10 1.42E-05 
GO:0050807 regulation of synapse organization 8 4.21E-05 
GO:0034765 regulation of ion transmembrane transport 13 5.56E-05 
GO:0005578 proteinaceous extracellular matrix 13 6.25E-05 
GO:0035725 sodium ion transmembrane transport 8 7.87E-05 
GO:0098794 postsynapse 13 9.39E-05 
 
Table 2.4 Legend: Top Significantly Decreased Pathways During Regeneration 
DAVID pathway analysis of RNAseq data showing the pathways of most significantly 
increased gene transcripts. 
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Chapter 2 Figures 
 
Figure 2.1: Sural Nerve Histology 
H&E and MCOLL (LBF, picrosirius, haematoxylin) staining of representative peripheral 
nerve fascicles. MCOLL stains myelin in blue and collagen in red. 
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Figure 2.2A: Correlation Matrix 
 
 
 
Figure 2.2B: Volcano Plot 
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Figure 2.2A: Correlation matrix  
Pearson’s r for the transcriptional profile of every subject vs every other subject. Scale 
bar: Correlation values range from 0.4 (blue- less similar) to 1 (red- more similar).  This 
visualization shows strong agreement among different profiles within each Stage, and a 
sharp distinction between Stages.  
 
Figure 2.2B: Volcano Plot 
 For differences between Stage 1 and Stage 2, log 2 scale fold changes (x axis) are plotted 
as a function of p-value (inverted log 10 scale- volcano plot). Results that exceed 
conservative q-value (q ≤ 0.0003) and fold change (|FC| >= 4) cutoffs are highlighted 
(blue- downregulated in Stage 2, red- upregulated in Stage 2). 
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Figure 2.3: Growth Factor Activity  
Heat map showing all significant differentially expressed (q< 0.05, |FC|>2) gene 
transcripts annotated with the GO term “Growth factor Activity” (GO:0008083). Genes 
are organized by Ward hierarchical clustering. Dendrograms are scaled to hierarchical 
clustering distance; longer branches represent more distant clusters. 
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Figure 2.4: Myelination 
Heat map showing all significantly differentially expressed (q< 0.05, |FC|>2) gene 
transcripts annotated with the GO term “Myelination” (GO:0042552). Genes are 
organized by Ward hierarchical clustering. Dendrograms are scaled to hierarchical 
clustering distance; longer branches represent more distant clusters. 
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Figure 2.5: Schwann Cell Transdifferentiation 
Heat map showing all significantly differentially expressed (q< 0.05, |FC|>2) gene 
transcripts annotated with the GO term “Epithelial-Mesenchymal Transition” 
(GO:0001837) or “Schwann Cell Differentiation” (GO:0014037). Genes are organized by 
Ward hierarchical clustering. Dendrograms are scaled to hierarchical clustering distance; 
longer branches represent more distant clusters. 
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Figure 2.6: Anti-Apoptosis 
Heat map showing all significantly differentially expressed (q< 0.05, |FC|>2) gene 
transcripts annotated with the GO term “Negative Regulation of Apoptotic Processes” 
(GO:0043066) or “Negative Regulation of Neuron Death (GO:1901215). Genes are 
organized by Ward hierarchical clustering. Dendrograms are scaled to hierarchical 
clustering distance; longer branches represent more distant clusters. 
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Chapter Three: The Neuro-Avatar Project 
Neuro-Avatar: A Reverse Translational Model of an Ongoing Cell Therapy Trial for the 
Treatment of Parkinson’s Disease3 
Introduction 
With the pro-regenerative phenotype of the sural nerve graft supported by 
transcriptomics, the next scientific questions posed by the clinical trial related to the 
neurobiology of the graft after implantation. How many graft cells survive the 
transplantation? Do the graft cells integrate with the surrounding tissue? How long do 
these cells survive? Furthermore, while the use of pre-lesioned tissue for its pro-
regenerative properties was supported by the scientific literature and now laboratory 
evidence, the investigators wanted to evaluate whether there were measurable 
differences between injury-naive versus post-injury nerve tissue used in grafts. 
Specifically, differences between graft cell count, integration with the host brain, and 
morphology of the graft cells between stage I and stage II graft tissue would illustrate 
differences in the graft’s effectiveness. 
In order to address these questions, the second aim of my project was to develop 
an animal model of the grafting procedure. This animal model would allow us to study 
the post-graft brain with histology and immunohistochemistry at multiple time points 
                                                          
3 Andrew S. Welleford, Nader El Seblani, Francois Pomerleau, Victoria Thompson, 
George E. Quintero, Craig van Horne, and Greg A. Gerhardt 
University of Kentucky College of Medicine 
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after grafting. The challenge posed by this project was to use the actual human nerve 
tissue collected from the grafting procedure; to best replicate the neurobiology of the 
human procedure. Considering the largest challenge to this approach to be immune 
rejection of human graft tissue, this led us to evaluate athymic nude rats as our model 
organism. 
Athymic nude rats are an immunodeficient strain of Sprague Dawley rats with 
reduced immune rejection of foreign tissue. The most common strain, the rnu strain, was 
first discovered in 1953 by Rowett et al. (Festing, Lovell, Sparrow, May, & Connors, 1978) 
These rats were observed to lack normal fur development, hence the nude moniker, and 
were also observed to have reduced immune system activity. This immune deficiency was 
found to be due to lack of thymus development and consequently impaired T cell 
maturation. This trait was linked to homozygous mutations of the rnu gene on 
chromosome 10. 
 Due to their reduced rejection of foreign tissue, athymic nude rats, along with 
athymic nude mice, have been used as an animal model for the grafting of tissue from 
other organisms (xenografting), including human tissue. In oncology research, athymic 
nude rats have been used for both anatomical and toxicology studies following grafting 
with human cancer cell and tissue lines. Kristjansen (Kristjansen, Roberge, Lee, & Jain, 
1994) describes the implantation of human tumor lines in athymic nude rats. Ozawa 
(Ozawa et al., 2002) describes growth of human glioblastoma xenografts. Chen (L. Chen, 
Tai, Brar, Leung, & Hsiao, 2015) describes changes in gut microbiome as a consequence 
of tumor grafting. Maruo (Maruo et al., 1982) describes grafting with human tumor lines 
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and an age-dependence of the rat host, with increased immune rejection observed in 
older rats. 
 Other athymic nude rat xenografting experiments include Beretta’s (Beretta et al., 
2017) grafting of human neural stem cells after TBI. Chesmel (Chesmel, Branger, 
Wertheim, & Scarborough, 1998) showed that human demineralized bone grafts elicit 
bone repair in a cranial defect in athymic nude rats compared to autografts. Keating 
(Keating, Isaacs, Mallu, & Baxi, 2015) demonstrated that human acellular nerve 
xenografts could be used to promote functional nerve repair in an athymic nude rat model 
of peripheral nerve injury. 
 These studies demonstrate the success of using athymic nude rats for human 
tissue xenograft experiments. However, there is no history of human peripheral nerve 
tissue xenografts within the brain of athymic nude rats. Thus, the aim of this project was 
to assess the feasibility of an athymic nude rat model of the human sural nerve grafting 
procedure. This model was dubbed the “Neuro-Avatar” for its use of human nerve tissue 
xenografted into an interspecies host. First, the logistics of coordinating human and 
animal surgeries are described. Next, a rodent stereotactic surgical grafting procedure 
was evaluated for feasibility, accuracy, and precision. Lastly, preliminary results of human 
graft tissue survival at two weeks and six months were assessed. 
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Methods 
Experimental Design 
Table 3.1 summarizes the experimental design. 16 total animals were planned: 8 
to be collected at 2 weeks post-surgery and 8 to be collected 6 months post-surgery. 
Within each group of 8 animals 4 were to receive tissue from Stage I surgerys (injury-
naive tissue) and 4 were to receive tissue from Stage II surgeries (injury-conditioned 
tissue). Because each human patient underwent a Stage I and Stage II surgery, a total of 
4 human patients would provide the tissue. 
Animal Surgery 
Athymic nude (Hsd:RH-Foxn1rnu) male rats (which have decreased immune 
rejection of human graft tissue) aged 2 months were ordered from [Vendors]. Animals 
were kept in University of Kentucky Division of Laboratory Animal Resources (DLAR) 
facilities in an infection control room except when in the surgical suite. 
Human sural nerve samples were collected during DBS surgeries. DBS at our 
institution is carried out in two stages: Stage I is followed by Stage II two weeks later (van 
Horne et al., 2017). For the Stage I tissue collection, the surgeon made a transverse 
incision through the skin of the lateral ankle, 2 cm superior to the lateral malleolus. The 
surgeon then identified the neurovascular bundle containing the sural nerve and 
associated artery and vein. The sural nerve was then separated from the bundle using 
blunt dissection. Next two black silk sutures were tied around the nerve roughly 1 cm 
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apart to mark the nerve. The section of the sural nerve between these sutures was then 
cut, a piece removed, and the surgical area sutured closed. 
The removed section of nerve was then stripped of its epineurium using 
microsurgical dissection in sterile saline. Individual fascicles of nerve fibers were 
separated using jeweler’s forceps and the perineurium was discarded. These fascicles 
were placed in conical microcentrifuge tubes and snap-frozen on dry ice before long-term 
storage at -80°C until assayed. For Stage II tissue collection, the surgical area from Stage I 
was reopened at the original incision. The surgeon located the suture markers on the sural 
nerve and removed a new piece of tissue from the distal stump of the nerve. This tissue 
was kept on sterile saline ice before implantation. Tissue was prepared for study 
intervention as in (van Horne et al., 2017) Sural nerve fascicles was transported from DBS 
surgery on ice. The fascicles were sectioned into 1 mm3 pieces, covered, and left on ice 
until insertion. 
The surgical field was prepared by laying out a sterile surgical drape over a 
preheated surgical warming pad set to 40 °C. The sterile empty surgical cannula was 
mounted to the arm of the stereotactic frame. This cannula was a 9-gauge needle with 
the tip blunted and smoothed with a dremel tool. A metal 0.1 mL syringe plunger was 
used as an inner stylet. 
Anaesthesia was induced using 5% isoflurane with supplemental oxygen in an anesthesia 
induction box. After anaesthesia induction, animals were secured to the stereotactic 
frame using a tooth bar and anaesthesia nose cone with 2.5% isoflurane with 
supplemental oxygen. The tooth bar was adjusted so that the dorsal surface of the 
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animal’s skull was level. Ear rods were placed securely in both auditory canals and 
adjusted until the animal was symmetrically secured to the stereotactic frame. Animals 
were kept on surgical warming pads during and after surgery.  
The dorsal surface of the animal’s skull was shaved using an electric razor from 
brows to ears. Next the skin was swabbed two times with cotton swabs soaked in 
betadine solution followed by wipe-down with two alcohol pads. 
After anaesthesia induction the animal was treated with the following: Rymadyl 
(10 mg/kg, SQ), Buprenorphine SR (1 mg/kg SQ), and Baytril (5 mg/kg IM). Dosing was 
individually calculated for each animal based on the animal’s mass, and the sustained 
release formulation of Buprenorphine provided analgesia for the entire post-surgery 
period. 
The animal’s body posterior to the surgical site was then covered with a second 
sterile drape. 
The surgeon donned sterile surgical gloves and made an incision down to bone 
with a scalpel along the midline from mid-brow through to the posterior crown ridge of 
the skull. The skin flaps were separated, blood was cleaned using sterile cotton swabs, 
and the superficial fascia was clipped using seraph clips and retracted, letting the weight 
of the seraph clips hold the incision open. Any actively bleeding blood vessels on the skull 
surface were cauterized using a cauterization pen. The skull surface was flushed with 
saline and dabbed dry with surgical gauze. The bregma was located at the convergence 
of the anterior suture and lateral sutures and marked using a permanent marker. The 
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cannula plus inner stylet tip was positioned directly on bregma and the Anterior-Posterior 
(AP) and Lateral-Medial (LM) stereotactic coordinate readout was zeroed. The 
coordinates used for the graft to the dorsal striatum were 1 AP, ±1 LM, and 4.5 DV. 
 The cannula plus inner stylet was then repositioned to the coordinates of 1 
(anterior) AP and -1 (Right) LM and lowered to just above the skull surface. This location 
on the skull was marked with a permanent marker. The cannula plus inner stylet was 
returned to bregma and the same procedure was repeated to mark the left side.  
Burr holes were drilled into the marked skull locations using a ball-tip drill bit. Care 
was taken to drill completely through the skull without applying pressure to the dura 
mater. After drilling, the burr hole was flushed with saline and cleared using sharp-tipped 
forceps. The dura was then pierced using the sharp-tipped forceps. The cannula plus inner 
stylet was reset to the 1 AP and -1 LM coordinates and lowered to the surface of the brain, 
watching for a reflection change of the dural surface indicating that the cannula had 
contacted the brain surface. The Dorsal-Ventral (DV) coordinate readout was set to zero, 
and the cannula plus inner stylet was inserted to a depth of 4.5 at a rate of 1 mm/minute 
to create a tract through the brain. This tract emulates the human surgery, which involves 
an insertion of a bullet-tipped rod prior to graft cannula insertion to create a tract through 
the brain. This insertion speed was achieved by lowering the cannula plus inner stylet 0.2 
mm at a time and waiting 10 seconds. After reaching a depth of 4.5, the cannula plus inner 
stylet was removed at the rate of 1 mm/minute. This process was repeated on the left 
side. 
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The cannula plus inner stylet, still mounted to the arm, was returned to the right 
side at 1 AP and -1 LM coordinates, the inner stylet was raised, and one 1 mm3 piece of 
nerve fascicle was loaded into the open end of the cannula. The cannula was lowered to 
the surface of the brain again, the DV coordinates were set to zero, and the cannula was 
inserted to a depth of 3.5 at a rate of 1 mm/minute to create a tract through the brain. 
This left a 1 mm space for the graft tissue to be inserted. This insertion speed was 
achieved by lowering the cannula plus inner stylet 0.2 mm at a time and waiting 10 
seconds. After reaching a depth of 3.5, the inner stylet was depressed, pushing the graft 
tissue into the brain. The cannula plus inner stylet was removed at rate of 1 mm/minute. 
If the graft tissue was seen to be adhered to the cannula then it was removed, as was the 
case in approximately half of the cases, a new piece was loaded into the cannula, and the 
insertion was repeated 1-2 times until successful graft delivery was achieved. After 
grafting, a sham insertion was performed on the control side using the cannula using the 
same procedure but without the graft tissue. 
After sham insertion, the burr hole was sealed using bone wax. The bone and 
tissue were wet thoroughly with saline and the skin flaps were pinched shut using curved 
blunt-end forceps. The surgical incision was stapled closed using 3-4 staples, taking care 
to align the cut ends of the incision. The animal was transferred to a cage on a preheated 
surgical warming mat until recovered from anaesthesia. Animal activity indicating 
anaesthesia was generally observed within 15 minutes of ending the surgery, and more 
vigorous activity was observed within one hour. Animals were kept for observation 
overnight, then returned to the animal care facility the day after surgery. No motor or 
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behavioral deficits were observed in the animals in the days or weeks following the 
surgery.  
Brain Collection 
 At the indicated date, animals were euthanized with 1 mL sodium pentobarbital 
solution (Lethal Plus) intraperitoneally followed by decapitation. Brains were dissected 
out and stored in 4% paraformaldehyde solution overnight. Brains were then transferred 
to a 40% sucrose solution with 0.1% sodium azide until tissue sectioning. 
 Brains were sectioned using a cryostat set to 45 um section thickness. Sections 
were collected sequentially in a 24 well plate in phosphate buffer with 0.1% sodium azide.  
Immunohistochemistry 
 Tissue sections were washed 3 times with 1x TBS for 6 minutes each. Sections 
were then etched with 7:2:1 etching solution (7mL TBS, 2 mL MeOH, and 1 mL freshly 
added H2O2) for 10 minutes, then washed with 1x TBS. Sections were then etched in 
sodium metaperiodate solution for 20 minute, then washed 3 times with 1x TBS-T for 10 
minutes. 
 Sections were blocked in 10% neutral goat serum (NGS) in TBS-T for 60 minutes. 
 Sections were then incubated in primary antibody (mouse anti-Human Nuclear 
Antigen, Abcam, Lot:GR183983-5) solution (1:500 in 3% NGS TBS-T) overnight. 
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 The following day the sections were washed in ~1 mL 3% NGS for 10 minutes, then 
incubated in 5 mL secondary antibody (biotinylated goat anti-mouse, Vector) solution 
(1:200 in 3% NGS TBS-T) for 60 minutes.  
ABC development solution was mixed according to manufacturer instructions 
(Vectastain ABC HRP Kit, Vector). 
Sections were washed in 1 mL 3% NGS TBS for 10 minutes 3 times, then incubated 
in 500 uL of ABC solution for 60 minutes. Sections were washed in TBS 1 mL for 10 minutes 
three times. 
VIP solution was added for 3 minutes, until the tissue visibly began to turn dark. 
Sections were washed in TBS for 10 minutes 3 times, then transferred to PB overnight. 
Sections were floated in PB onto slides, then cover slipped using Cytoseal. 
Remaining avatar brain regions were preserved in cryoprotectant (300 mL 
ethylene glycol, 250 mL glycerol, PB added to 1 L volume) and kept at -20° C. 
Results 
Feasibility of tissue grafting procedure 
The first concern in developing this animal model of the sural nerve grafting 
procedure was the feasibility of implanting fresh human nerve tissue collected from 
surgery into rodents. The coordination of human tissue collection with animal 
implantation was successful. All 16 animals indicated in the experimental design received 
a graft of human tissue from four human participants. Following surgical dissection of 
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fascicles the human peripheral nerve fascicles were delivered to the animal surgery suite 
on ice and kept on ice until grafted into the animals. This was achieved by beginning the 
animal surgery while the human peripheral nerve tissue was being collected and surgically 
dissected, so that the insertion of graft tissue occurred shortly after the human tissue 
arrived to the surgical suite. Communication between the animal surgical team and the 
human tissue collector ensured that these events were coordinated. 
Each rodent surgery session involved two animals being implanted with tissue 
from the same human subject’s surgery: one animal to be evaluated two weeks later, and 
one animal to be evaluated six months later. These two rodent surgeries were performed 
sequentially, with the first insertion occurring as soon as the human tissue arrived, and 
the second insertion occurring after closing the first animal and preparing the second 
animal. The animal to be collected at two weeks was not indicated at the time of surgery, 
and was assigned by the experimenters at two weeks post-surgery. One or two human 
surgeries occurred per day, meaning that up to four total rodents were implanted each 
surgery day. On days with two human surgeries the tissue collection was separated by 
several hours, allowing for the completion of the first set of rodent surgeries before the 
second tissue sample arrived. Each animal's surgery took approximately two hours from 
anaesthesia induction to surgical incision closing. 
 Each human subject underwent two surgeries: a Stage I and Stage II DBS surgery 
spaced two weeks apart. With two animals grafted from each human surgery, a total of 
four human participants provided tissue for 16 rodent surgeries. 
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Athymic Nude Rat Tolerance of Stereotactic Surgical Grafting Procedure 
The surgical procedure was well-tolerated overall by athymic nude rats. All 16 
animals indicated in the experimental design successfully underwent the grafting 
procedure. One uncounted animal died of cerebral hemorrhage during the surgery as a 
result of the bone drill slipping approximately one millimeter deep into the brain while 
drilling a burr hole. This occurred before grafting the human tissue, and a backup animal 
was used to carry out the grafting procedure for that tissue sample. A different animal 
recovered from the grafting procedure anaesthesia and was observed to resume activity 
that day, but died the following night from suspected respiratory arrest. This animal was 
counted in the total of 16 grafted animals but excluded from analyses as it did not survive 
to the two week time point. 
Accuracy and Precision of Stereotactic Surgical Grafting Procedure 
Histology of the brains post-implantation shows that not all cannula insertions 
were successful in reaching the dorsal striatum. The depth of the graft or control tracts 
did not reach the targeted depth. Evidence of brain compression and resulting contusion 
were visible. Taken together, these suggest that the graft cannula in its current design 
creates drag when it is inserted into the brain tissue, which compresses brain tissue and 
causes contusions while not reaching the desired depth. 
Preliminary Analysis of Human Graft Cell Survival 
In the brains of animals successfully grafted, HNA staining was positive on the graft 
side along the tract of tissue insertion. (Figure 3.1 and 3.2)  One control tract out of the 
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eight animals was also positive for HNA. Peripheral nerve tissue was visible two weeks 
following the grafting procedure. (Figure 3.3) This tissue is striated and darkly-staining 
against HNA. 
HNA positive nuclei were observed throughout the brain of grafted animals. Figure 
3.4 shows HNA-positive nuclei within the corpus callosum. Two main HNA-positive cell 
types were observed: HNA-positive nuclei and HNA-positive cell surfaces. (Figure 3.5) 
As Figure 3.7 summarizes, at two weeks post-surgery there was no difference in 
diameter of HNA-positive staining from the graft tract between animals grafted with 
Stage I (injury-naive) tissue and animals grafted with Stage II (injury-conditioned) tissue. 
In addition, from preliminary staining of the six months post-implantation group, 
immunofluorescence showed presence of HNA-positive cell nuclei within the target 
region of the dorsal striatum in some animals, HNA-positive cell nuclei in the cortex but 
not dorsal striatum of other animals, and no HNA staining in some animals. These results 
support the survival of human graft cells in the animal model up to and exceeding six 
months. (El Seblani et al. In preparation.) 
Discussion 
Surgical procedure 
Successful delivery of human peripheral nerve tissue to the rat dorsal striatum 
presented several challenges that needed to be overcome. First, a custom cannula was 
designed for the Neuro-Avatars. The cannula used in human surgeries was designed to 
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hold five 1 mm3 graft pieces, whereas the rodents were to receive only one 1 mm3 piece. 
The relative size of even one 1 mm3 nerve segment is much larger than the human 
counterpart, necessitating a rodent cannula to be designed to minimize brain volume 
displacement. This limited the size of the graft cannula. We improvised using a 9-gauge 
needle blunted and rounded using a Dremel tool. The inner stylet used to deploy the 
tissue was a small metal syringe plunger from a 0.1 mL syringe, which fit securely within 
the cannula. 
Even with the customized cannula, the grafting cannula did not reach the targeted 
brain depth in all insertions as evidenced by histology of the track. This is possibly due to 
blunt end of the cannula not effectively pushing into the brain tissue, even following 
piercing of the dura mater with sharp-tipped forceps. The empty cannula with inner stylet 
inserted was used to both create a track and insert the nerve tissue. The human surgery 
uses a bullet-tipped rod to create a tract for the graft cannula. A similar tool with an 
appropriate diameter will be needed to reliably create a tract to the desired depth in the 
Avatars. 
A delivery cannula of a different design would improve the Neuro-Avatar animal 
model. There was a small gap between the cannula and the inner stylet and peripheral 
nerve tissue would often stick to the cannula and be drawn back out along with the 
cannula, necessitating re-insertion of the graft in several animals. Using the human 
cannula is not feasible given the proportionately large diameter compared to the rat 
brain. In the human surgery there are instances of the same problem occurring: nerve 
tissue getting caught between the cannula and inner stylet and not successfully being 
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deployed in the brain. A surgically appropriate material that can create a complete seal 
between the cannula and inner stylet, such as an inert silicone tip, may improve the 
reliability of tissue delivery. The sticky nature of peripheral nerve tissue itself is another 
contributing factor. An inert coating of the nerve tissue might improve the reliability of 
tissue delivery; however such an addition would not match the human trial, and the 
human trial is limited by FDA approval for additional substances to be inserted into the 
brain. Because the nerve tissue is autologous and not exposed to any treatment except 
surgical dissection it is considered permissible by the FDA for use in this clinical trial. If the 
Avatars are to model the human surgery as closely as possible then inserting additional 
substances must be avoided. 
An athymic nude rat atlas should be used for precise surgical planning. Athymic 
nude rats are smaller than their wild-type (WT) counterparts and have smaller skulls and 
brains. Stereotactic coordinates may differ between athymic nude and WT rats, especially 
for more precise targets such as the Substantia Nigra. This led to the amendment of 
stereotactic coordinates from the first surgeries to the last. 
As this project was the first step in developing the Neuro-Avatar animal model, 
the researchers decided to use an unlesioned animal rather than a dopamine-depletion 
model using 6-OH-dopamine lesion. This allowed for the evaluation of the grafting 
procedure independent of other experimental challenges of consistent animal dopamine 
depletion. Future studies could use a 6-OH-dopamine lesion model or another model of 
Parkinsonism to study effects of the graft tissue in a Parkinsonian brain. 
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Contamination of the control side with HNA-positive staining was observed in one 
animal. This was likely due to human cells remaining on the graft cannula after the 
insertion of the graft. In the future two identical cannulas should be used, and only one 
allowed to come in contact with the graft tissue. 
Human graft tissue  
HNA-positive cell staining supports the survival of human cells at two weeks, and 
preliminary analysis suggests graft cell survival up to and beyond six months. (El Seblani 
et al. In preparation.) The presence of HNA-positive cells in the area of the graft indicates 
that the graft survives in the brain of immunodeficient athymic nude rats. This finding 
suggests that in an autologous human graft recipient we would also expect graft cell 
survival at six months.  
Conclusions 
These results support the development of xenograft animal model of the human 
sural nerve graft procedure. Optimizations of the surgical protocol, in particular the 
development of a tract-forming rod analogous to the human surgery, are described. 
Survival of human tissue for at least six months in the athymic nude rats is evidenced by 
HNA staining, suggesting that within humans the nerve graft tissue implanted in the DBS 
Plus clinical trial survives within the host brain. 
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Chapter 3 Tables 
Target Total n Treatment Tissue 
Source 
Group 
total n 
Time Post-Graft of 
Collection 
2 weeks 6 
months 
Dorsal 
Striatum 
16 Nerve graft (R) 
Sham insertion (L) 
Stage I 
DBS 
8 4 4 
Stage II 
DBS 
8 4 4 
 
Table 3.1: Avatar Project Experimental Design 
A total of 16 animals were grafted with the target of dorsal striatum. Each animal received 
a nerve graft inserted in the right hemisphere and a sham insertion of an empty cannula 
on the left hemisphere. A total of eight animals received tissue from Stage I of human DBS 
surgery and eight animals from Stage II of human DBS surgery. Within each group of eight, 
brains from four animals were collected at 2 weeks post-surgery and brains from the 
remaining four animals were collected at 6 month post-surgery. 
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Chapter 3 Figures 
Figure 3.1: Coronal Histology of Avatar brain with HNA Staining 
 
Figure 3.2: Coronal Histology of Avatar brain with Nissl Staining 
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Figure 3.1 and Figure 3.2: Coronal Histology of Avatar brain 
Anti-Human Nuclear Antigen (HNA) (Fig 1) and Nissl (Fig 2) staining of animal R1, two 
weeks post-graft. The right hemisphere is marked with a cut visible on the right. The graft 
tract is visible in the right hemisphere. A control tract was not visible in this animal. 
Evidence of brain contusion from blunt pressure of the control cannula is visible in the 
left hemisphere. 
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Figure 3.3: Graft tissue with HNA staining 
HNA staining showing putative graft tissue. Longitudinal fibers of the peripheral nerve 
tissue are visible with robust anti-HNA staining. Multiple HNA-positive cells are visible 
surrounding the graft tissue. Diffuse anti-HNA staining is also seen surrounding the graft 
and HNA-positive cells. 
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Figure 3.4: Graft Cell Infiltration with HNA Staining 
HNA-positive cells are visible throughout the right hemisphere. Note HNA-positive cell 
nuclei within the corpus callosum. This suggests migration of HNA-positive cells through 
the brain of the grafted animal beyond the borders of the graft. 
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Figure 3.5: Cell Morphology with HNA Staining 
20x magnification showing morphology of HNA-positive cells. These cells appear to be 
part of the rat brain, and their shape suggests that they are neurons. The nuclei of these 
cells are not positive for HNA. It is possible that these are MHC-expressing cells that are 
presenting HNA after graft cell death. 
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Figure 3.5: Radius of HNA-positive Staining, Graft vs. Sham 
 
Figure 3.7: Radius of HNA-positive Staining, Stage I vs. Stage II Tissue 
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Figure 3.6 and Figure 3.7: Radius of HNA-positive Staining 
Quantification of HNA-positive staining radius in each brain. There was significantly higher 
staining radius in graft vs control tracts. Note that only one rat brain showed HNA staining 
on the control tract; a suspected contamination of the control cannula with human tissue. 
There was no statistically significant different in the radius of HNA staining from Stage I 
vs Stage II graft tracts. 
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Figure 3.8: Avatar Surgery Setup 
Picture of rat within stereotactic frame. 
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Figure 3.9: Avatar graft and Control Tracts 
No Primary Antibody (Negative Control) 
 
 
 
No Secondary Antibody (Negative Control) 
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Randomized 2 
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Randomized 3 
 
 
Randomized 4 
 
 
 
 
 
 
 
 
 
81 
Randomized 5 
 
 
Randomized 6 
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Randomized 8 
 
 
Figure 3.9: Avatar graft and Control Tracts 
Images of graft and control tracts for all grafted animals. 
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Chapter Four: Clinical Data 
Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s 
disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, 
and clinical outcome4 
Introduction 
The motor symptoms of Parkinson’s disease (PD) are primarily related to the 
degeneration of dopaminergic neurons within the midbrain. One of the hallmarks of the 
disease is the continual progression of symptoms associated with ongoing cell loss. 
Although medical and surgical therapies can ameliorate some of these symptoms, 
disease progression leads to treatment-resistant symptoms that are often accompanied 
by troublesome fluctuations and medication side effects. Unfortunately, no treatment 
slows or halts disease progression. Thus, altering the course of clinical decline in PD is 
perhaps the largest unmet need facing patients, researchers, and clinicians. (Kalia & 
Lang, 2015)  
The majority of surgical research efforts to alter disease progression have 
focused on either cell replacement strategies or the delivery of growth factors that 
target the restoration of dopaminergic neurons. Transplantation of fetal dopaminergic 
tissue has not demonstrated significant clinical improvement in randomized double-
blinded control studies. (Kidd et al., 2013) However, pronounced long-term 
                                                          
4 Published as: Craig G. van Horne, Jorge E. Quintero, John T. Slevin, Amelia Anderson-
Mooney, Julie A. Gurwell, Andrew S. Welleford, John R. Lamm, Renee P. Wagner, and 
Greg A. Gerhardt. "Peripheral nerve grafts implanted into the substantia nigra in 
patients with Parkinson’s disease during deep brain stimulation surgery: 1-year follow-
up study of safety, feasibility, and clinical outcome." Journal of neurosurgery 129, no. 6 
(2018): 1550-1561. 
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improvements in several patients (Barker, Barrett, Mason, & Björklund, 2013) have 
prompted a new round of investigations in Europe (TRANSEURO; clinicaltrials.gov 
database registration no.: NCT01898390), despite ongoing moral and ethical issues 
surrounding the use of human fetal tissue as donor material. Meanwhile, strategies for 
growth factor delivery have focused on the use of a single factor and have included direct 
infusion of the factor, such as glial cell–derived neurotrophic factor (GDNF) (Steven S Gill 
et al., 2003), (John T. Slevin et al., 2005) or the infusion of a viral vector, such as AAV-
neurturin, capable of initiating the production of the factor. (Bartus et al., 2013) 
Intraparenchymal GDNF delivery has shown promise in preclinical studies that failed to 
show significance in a phase II trial. (Lang et al., 2006) Despite promising early results, 2 
randomized controlled studies with AAV-2 neurturin (CERE-120) did not meet their 
primary end points. (Marks et al., 2010; Marks et al., 2008) 
These clinical studies have clearly identified some of the hurdles in developing 
neurorestorative therapies. Identifying the right factor(s), target(s), and methodology 
for optimum delivery poses major challenges. An additional consideration is that 
patients who are appropriate for enrollment in surgical implantation therapy trials are 
often at a stage in their disease where deep brain stimulation (DBS) is now the standard 
of care. This is especially relevant for studies aimed at changing disease progression. 
From a patient-centric view, choosing to participate in a long-term trial to assess 
alteration of disease progression may mean foregoing the benefits of DBS. For a study 
that may last 1, 2, or more years, having patients with PD forego the standard of care 
for so long for unproven therapies creates a set of ethical dilemmas. 
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Considering these challenges, we have identified a new approach to investigate 
the ability to alter disease progression. We use a cell-based graft that consists of 
peripheral nerve tissue as a source of growth factors and growth-promoting proteins for 
delivery into the parenchymal region with dopaminergic cell loss. We deploy the tissue 
grafts in the substantia nigra immediately following stimulating electrode placement 
into the subthalamic nucleus (STN) in patients with PD undergoing DBS surgery. 
Peripheral nerve tissue is an abundant source of Schwann cells, which support 
and maintain axonal function and metabolism. (Kidd et al., 2013) Following injury to the 
nerve, Schwann cells transdifferentiate into repair cells and support axonal regeneration 
in the peripheral nervous system. (Jessen & Mirsky, 2016) The specific mechanism 
involves the activation of the transcription factor, c-Jun, which enables 
transdifferentiation through the upregulation of the production and release of growth 
factors, (Taylor & Bampton, 2004) the downregulation of regulatory maintenance 
programs, the reentry of the cell into the cell cycle, and the initiation of chemical 
signaling in order to attract the migration of macrophages to assist in the process of 
regeneration. (Arthur-Farraj et al., 2012) The growth factors produced include those that 
have been shown to promote and maintain dopaminergic neurons in experimental 
conditions: GDNF, (Henderson et al., 1994) brain-derived neurotrophic factor, (Meyer, 
Matsuoka, Wetmore, Olson, & Thoenen, 1992) and neurotrophin 3. (Funakoshi, 1993) 
We previously reported the safety and feasibility of grafting autologous 
peripheral nerve tissue into the substantia nigra. (van Horne et al., 2017) This study 
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presents the full experience of the clinical trial that enrolled 8 participants and the 
clinical outcome data at 1-year postimplantation. 
Methods 
This study was designed as a 12-month, investigator-initiated, open-label, single-
center, phase I trial to assess safety and feasibility as the primary end points. This study 
was registered with (registration no. NCT01833364, clinicaltrials.gov). Clinical data were 
collected to evaluate the potential of the graft to affect the clinical course of PD 
symptoms. This study was approved by the University of Kentucky institutional review 
board, and informed consent was obtained from all study participants. 
Patient Selection 
Eight patients with a diagnosis of idiopathic PD, who had been selected and 
provided consent to receive bilateral DBS of the STN, were informed about the study 
and gave both assent and formal consent to participate. Inclusion criteria were age 40–
75 years; greater than 5-year history of symptomatic, idiopathic PD; and an ability to 
participate in all follow-up appointments. As part of our standard preoperative DBS 
protocol, participants were evaluated using the Unified Parkinson’s Disease Rating Scale 
(UPDRS), both on and off medication, and underwent a formal neuropsychological 
evaluation. The Parkinson’s Disease Questionnaire–8 was used to assess overall quality 
of life. 
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Safety and Feasibility 
Patients were monitored for both perioperative and long-term postoperative 
adverse events. Clinical monitoring included the perioperative time points through the 
conclusion of the study at the 12-month time point. During this time period, adverse 
events were recorded from clinical reports, chart reviews, and specific queries during 
the clinical visits. All adverse events were submitted to and reviewed by the Data and 
Safety Monitoring Board (DSMB) at the University of Kentucky. Adverse events were 
graded as mild, moderate, or severe, as defined by the Medical Dictionary for Regulatory 
Activities (version 11.0). Serious adverse events were designated as any event that 
resulted in death, disability, prolonged or new hospitalization, or were life threatening 
or required medical or surgical intervention. A 1.5-T MRI study was performed within 48 
hours postoperatively and at 12 months. Adverse events were categorized as either 
related to the graft, graft procedure, DBS surgery, DBS therapy, or not related to either 
surgical or therapeutic component. 
Surgical Implantation 
The surgical components of stimulator placement and graft placement have 
been described in detail (van Horne et al., 2017) and are summarized in brief below. As 
is typical at our institution, DBS surgery takes place over two stages. (van Horne et al., 
2015) Stage I involves the implantation of the pulse generator and extensions. Stage II is 
when the DBS electrodes are implanted. The trajectory of the stimulating electrode to 
the STN was planned based on visualized targeting. Preoperative susceptibility-weighted 
imaging (SWI) MR sequences were used for target localization, and T2-weighted and 
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magnetization-prepared rapid acquisition gradient-echo sequences with contrast were 
used to establish trajectories that avoided the sulci, ventricles, and vasculature. Entry 
through the cortical gyri in the vicinity of the coronal suture allowed for lead trajectories 
that passed through the long axis of the STN. Plans were created using Brainlab software 
(iPlan Stereotaxy 3.0) for use with the Cosman-Roberts-Wells frame (Integra). DBS 
surgeries were performed while the patient was awake with microelectrode recording 
and test stimulation. (van Horne et al., 2015) 
Once the stimulating electrodes were successfully placed, the graft was 
implanted unilaterally into the substantia nigra contralateral to the most affected side 
based on the UPDRS part III scores. The 5-mm-long target zone within the substantia 
nigra was located between 1 mm and 6 mm deep to the inferior border of the STN. The 
inferior border was identified intraoperatively by the electrophysiological activity that 
was recorded during stimulating electrode implantation. A guide cannula (1.8-mm-wide 
outer diameter; FHC, Inc.) was then placed within the graft target zone. The graft 
implantation trajectory was parallel to that of the stimulating electrode, at 
approximately 3 mm posterolateral, and did not require the creation of an additional 
burr hole. 
The sural nerve that had been prepared and identified in stage I (van Horne et 
al., 2017; van Horne et al., 2015) was then re-identified, and a 2-cm-long segment of the 
nerve was harvested distal to the previous transection site. The nerve segment was 
rinsed in sterile saline, the epineurium was removed, and the fascicles were then cut to 
produce smaller, approximately 1-mm-long segments. Five to 6 segments were then 
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loaded into the custom-made graft cannula, and the graft cannula was placed to the 
target through the same burr hole used for the stimulating electrode. After graft 
placement, the incisions were closed with subcutaneous sutures. 
Postoperative Evaluation 
After DBS and graft implantation, participant were admitted overnight. Each 
participant underwent postoperative MRI to confirm electrode placement and to 
evaluate the region of the graft target zone. Stimulator programming was initiated in 
the immediate postoperative period before discharge. Patients underwent clinical 
follow-up through routine postoperative visits, programming visits, and postoperative 
study visits. Medication changes were documented and reported as the levodopa 
equivalent dose (LED). (Pahwa, Wilkinson, Overman, & Lyons, 2003) For UPDRS testing, 
participants stopped taking medication at least 12 hours before undergoing UPDRS 
testing. After surgery, participants (if on medication) stopped medication 12 hours 
before UPDRS testing and turned off DBS 12 hours before UPDRS testing, except for the 
one participant (participant 2) who stopped taking medication and turned off the DBS 
stimulator 3 hours before UPDRS testing. 
Neurocognitive Testing and Analysis 
The neurocognitive assessment battery was designed to meet the Movement 
Disorders Society’s Task Force Guidelines for determining mild cognitive impairment and 
PD dementia. (Emre et al., 2007; Litvan et al., 2012) Level II criteria for comprehensive 
assessment of cognition in patients with PD include multiple measures of executive 
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functioning, attention, working memory, language, memory, and visuospatial functions. 
Some subtests of these measures were used to assess both verbal and psychomotor 
speed. In addition, an estimate of premorbid function and a brief measure of general 
intelligence were included to aid clinical judgments of changes in individual cases and 
provide a comprehensive neurocognitive assessment. Affective and emotional 
symptoms were measured using a self-reported measure to complement clinical 
assessment during the patient interview. Postoperative evaluations were completed 
approximately 1 year after the DBS procedure (mean ± SD 14.98 ± 4.73 months) using 
alternate forms of measures, where available, to minimize practice effects between 
assessments. The full assessment protocol for both the preoperative and postoperative 
evaluations involves a clinical interview with a neuropsychologist, with participation by 
both the participant and an informant, and battery administration by a clinically 
licensed, master’s level psychometrician. All performances on the neurocognitive 
measures were quantified using appropriate normative sources, and all 
neuropsychological data were interpreted by a neuropsychologist. Analysis focused on 
individual changes between the preoperative and postoperative scores. 
Data Analysis 
Results were analyzed using the t-statistic (or Wilcoxon matched-pairs test for 
nonparametric values) for paired group means between the baseline and 12-month 
assessments (Prism 6.0, GraphPad Software Inc.). Mean values are presented with 
standard deviation. The minimal level of significance was p ≤ 0.05 (2-tail criterion). 
Evaluation of the neurocognitive data were completed using IBM SPSS (version 23) with 
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the majority of scores in standard form (mean 100, SD 15). Raw scores were compared 
as the affective measure. Due to the small sample size, the normality of the score 
distribution was examined, and the results suggested discordant normality for some 
scores (e.g., p = 0.03 for the presurgical riddles subtest of the Kaufman Brief Intelligence 
Test-2 vs p = 0.10 for the postsurgical results, Kolmogorov-Smirnov test). Given this 
finding, nonparametric analysis with the Wilcoxon signed-rank test was employed to 
examine the neurocognitive data. One participant was included in only some analyses 
because of differences in the presurgical battery construction. 
Results 
Patient Summary 
Eight participants—6 males and 2 females—met the criteria for participation and 
successfully completed the study protocol. The mean participant age was 62.9 ± 9.2 
years, and the mean disease duration was 9.8 ± 3.9 years. Because of family issues, 1 
participant was not able to participant in the intermediate therapeutic evaluation visits 
(6 and 9 months) but was able to complete the 12-month evaluations. With respect to 
safety and adverse event reporting, the participant was evaluated by the local 
movement disorders neurologist and was in close communication with our study team 
throughout the study. 
Safety 
All adverse events were submitted to and reviewed by the DSMB at the 
University of Kentucky and are summarized in Table 4.1. The events listed include all 
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events that presented from the first stage of the surgery through study closeout at 12 
months postimplantation. One adverse event, superficial cellulitis surrounding the ankle 
incision, was graded as mild and categorized as serious and related to the graft 
procedure. The participant was treated with a 10-day course of antibiotics, and the 
cellulitis resolved. No other adverse events were related to graft harvesting or graft 
implantation. Two adverse events, urinary retention and headache, were mild, not 
serious, and related to the DBS surgery and resolved without further intervention. Three 
events were deemed to be mild, not serious, and not related and included falls and 
headache. One event, hypomania, was mild, not serious, and related to DBS stimulation 
and resolved promptly after changing the stimulation of the more proximal set of 
contacts of the stimulating electrodes. With respect to DBS surgery, there were no 
observed infections, hardware malfunctions, or skin erosions. With respect to feasibility, 
all participants underwent successful graft harvesting and implantation without 
complication or significant delay. 
MRI Data 
MR images (1.5 T) were obtained within 48 hours and at 12 months to evaluate 
the midbrain region for evidence of abnormalities, including swelling, edema, or contrast 
enhancement. The MR images from the 48-hour time point have been reported 
previously.38 There was no evidence of swelling or edema on the T2-weighted images 
and no evidence of enhancement on the T1-weighted contrast images within 48 hours 
or at 12 months. The MRI data also confirmed the appropriate placement of the DBS 
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electrodes within the STN (Figure 4.1). There was no evidence of complications, such as 
hemorrhage or stroke, along the trajectories of the electrodes. 
Clinical Measures 
A summary of the clinical data is included in Table 4.2, with individualized scores 
listed in Table 4.3 and 4.4. Analysis of each of the 4 parts of UPDRS revealed that all parts 
showed a decrease (improvement) from baseline. Because UPDRS part III in the off state 
is the most appropriate score to evaluate any potential influence from the graft, we 
focused our subgroup analysis on the UPDRS part III scores. Collectively, the part III off 
scores at 12 months (25.1 ± 15.9 points) decreased from baseline (32.5 ± 9.7 points), but 
the difference was not statistically different (Table 4.2). We also individually scored each 
participant (Figure 4.2) with respect to changes in baseline using values based on 
clinically important differences (CIDs). According to Shulman et al., (Shulman et al., 
2010) minimal, moderate, and large CIDs are 2.5, 5.2, and 10.8 points from baseline, 
respectively. 
 
Individual changes in motor scores (UPDRS part III) while off DBS and off 
medication therapy from baseline to 12 months after surgery. Minimal (2.5 points), 
moderate (5.2 points), and large (10.8 points) CIDs are indicated. Each symbol 
represents a different participant.  
We further analyzed the UPDRS part III data by performing subgroup evaluations 
of the collective data of all participants to investigate potential differences among 
symptom subsets, including tremor, rigidity, bradykinesia, and axial symptoms (speech, 
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facial expression, gait, posture, postural instability, and body bradykinesia), and 
between lateralized scores relative to graft placement (ipsilateral vs contralateral). 
Subgroup analysis demonstrated larger improvements in tremor and rigidity and minor 
improvements in bradykinesia and axial symptoms (Figure 4.3. The analysis of the 
lateralized scores showed a greater overall reduction in scores on the side contralateral 
to the graft than the ipsilateral side (Figure 4.4). 
Neurocognitive Data 
Analysis revealed that neurocognitive performance remained largely stable 
between the preoperative and postoperative time points, with some notable exceptions 
(Table 4.5). Some degree of improvement was postoperatively seen on the 
constructional praxis task (block design test of the Wechsler Adult Intelligence Scale–
Fourth Edition; T = 0, p = 0.04) with a large effect size (r = −0.55). A subtle change was 
observed in the approach to the problem-solving task, on which responses became less 
nonsystematic and random at the postoperative time point (nonperseverative errors on 
the Wisconsin Card Sorting Test–64 Card Version; T = 3, p = 0.6). This change approached 
statistical significance, and the effect size was large (r = −0.50). The clinical significance 
of these changes is unknown because both may be influenced by repeated exposures to 
the stimuli and/or improvements in fine motor function. A significant decline was 
observed in phonemic fluency only (Controlled Oral Word Association Test; T = 0, p = 
0.02) with a large effect size (r = −0.62). Levels of affective distress remained stable 
between the presurgical and postsurgical evaluations (T = 10, p = 0.92). 
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Discussion 
As the first-ever reported attempt at combining a surgically delivered therapy 
with DBS, we designed this pilot study to test the safety and feasibility of this approach. 
Although we did not have a formal control group, we compared our results to similar 
patients in our database and to results in the literature where applicable. Specific risks 
for the procedure itself have been covered in detail in our previous publication, (van 
Horne et al., 2017) and as such we focus on the inclusive, longer term adverse events of 
the graft itself. 
The adverse events collected throughout the study and monitored by our institutional 
DSMB showed only 1 serious adverse event that that could be attributed to the grafting 
procedure itself. This was superficial cellulitis at the graft harvest site that responded to 
oral antibiotics. The other adverse events reported were not related to the graft 
procedure or the graft and were similar to the adverse events reported by the DBS 
patients without a graft through 12 months (University of Kentucky DBS database; data 
not shown). Our total adverse events were also similar to those previously reported by 
other centers. (Fenoy & Simpson, 2014; Patel et al., 2015) 
MR images obtained at 12 months postoperatively showed no evidence of signal 
abnormality or contrast enhancement in the region of interest (ROI) based on 
preoperative targeting. These images were compared with the baseline and 24-hour 
postoperative MR images. Used in this way, MRI is able to provide information regarding 
potential adverse interactions of the graft with the surrounding parenchyma, such as 
inflammation, edema, or breakdown of the blood-brain barrier. MRI does have its 
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limitations in relation to our protocol. Our ROI is very small, measuring only 1.5 mm in 
diameter, and the presence of a DBS electrode limits our scan potential to 1.5 T. 
Additionally, the artifact from the electrode can be substantial, especially on SWI 
sequences. Functional MRI is not practical due to poor resolution with 1.5 T and the need 
for the patient to remain still for a prolonged period of time, which is especially difficult 
for many patients because the stimulator must be turned off during the scanning 
process. Although DaTscan (123I-ioflupane) analysis (GE Healthcare) does hold some 
promise for evaluating the potential effects on the dopaminergic terminal field in the 
striatum, the lack of dopamine transporters on the cell bodies in the substantia nigra 
precludes its use for directly evaluating the region. MRI remains a useful tool for 
evaluating tissue integrity within the ROI of the graft but lacks the utility for assessing 
graft survival or function. 
Clinical Data 
In this study, we report all components of the UPDRS examination. All 
components of our clinical evaluation, which are noted in Table 4.2, showed 
improvements, although none of the changes were statistically significant. Taken 
together, these results provide evidence that the grafting procedure in addition to DBS 
therapy does not negatively influence the therapeutic effect of DBS. 
As noted previously, UPDRS part III is the most relevant clinical measure for 
evaluating potential influence from the graft; the scores from the other components of 
the examination are heavily influenced by the continual presence of DBS and medication 
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therapy. Thus, the UPDRS part III off-therapy scores give a reasonable and practical way 
to measure a participant’s baseline progression of motor symptoms. 
Using each individual’s preoperative scores as baseline, the composite scores of 
all participants showed an overall decline by 7.4 points. This compares to an expected 
annual increase of 3–5 points over time in patients with PD. (Guimaraes et al., 2005; 
Kieburtz, 2003; Venuto, Potter, Dorsey, & Kieburtz, 2016) 
In considering potential outcome measures for this and future studies that 
employ this paradigm, we chose to evaluate participants according to clinically 
important differences, as described previously. (Caplan, 2007; Shulman et al., 2010) The 
observed changes in the scores of the individual participants demonstrated that 6 of the 
participants scored lower (better) than baseline while 2 scored higher (worse). Using the 
UPDRS part III categorization for clinically important differences to assess the 6 
participants who improved, 2 participants had a large CID, 3 had a moderate CID, and 1 
had minimal CID. 
Further analysis of the data subset showed that the biggest improvement in 
scores was in the domain of tremor. We do not think that this could be accounted for as 
a holdover from DBS therapy because tremor is one of the first symptoms to return after 
DBS is turned off. (Temperli et al., 2003) In addition, we chose a more conservative DBS-
off time interval of 12 hours for motor testing. Although 3 hours off DBS is adequate for 
off testing, (Temperli et al., 2003) we thought that an extended time would provide a 
more accurate assessment for scoring. 
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A comparison of unilateral versus contralateral scores showed improvements on 
both sides, but a larger improvement was noted on the side of the body contralateral to 
graft placement. Improvements unilateral to surgical therapies for PD have been 
reported for DBS (Chung, Jeon, Kim, Sung, & Lee, 2006; Walker, Watts, Guthrie, Wang, 
& Guthrie, 2009) and for the infusion of GDNF. (John T. Slevin et al., 2005) 
We documented the change in PD medications in LDEs and report a large 
decrease in the total daily doses. The large variability is accounted for by the 2 
participants who continued on their regimen with lower doses, whereas the other 6 
participants remained off their medications for the 12-month study period. We cannot 
determine whether the grafts had any impact on this finding. DBS of the STN allows for 
a substantial reduction in PD medication (Molinuevo et al., 2000) compared with DBS of 
the globus pallidus internus. (Williams et al., 2014) We also note that with our protocol 
we implemented an intention-to-treat approach and therefore did not manipulate 
medications as indicated by the UPDRS part III results while DBS was on. As such, in 
future studies that evaluate potential disease-altering therapies in the setting of DBS 
therapy, we recognize that medication changes are important to monitor but are not a 
critical end point for measuring graft function. 
Neurocognitive Outcome 
Our analysis suggests that, despite some changes, postoperative neurocognitive 
functioning remained largely stable in this group and the levels of affective distress 
remained stable as well. Significant decline was limited to phonemic verbal fluency only, 
and this is commonly observed after DBS, in particular with STN stimulation. (Combs et 
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al., 2015) Potential improvements were observed in constructional praxis and abstract 
problem solving. However, these changes are of unknown clinical significance, as noted 
above, because these outcomes may have been affected by repeated exposure to these 
stimuli and improvements in fine motor functions. Furthermore, potential practice 
effects may have masked the underlying decline to some degree, although the true 
extent of that potential influence cannot be estimated accurately. However, because the 
time between evaluations was an average of more than 14 months, practice effects may 
have been less of a concern. In addition, the salient literature suggests that individuals 
with cognitive vulnerabilities such as mild cognitive impairment may not benefit from 
practice effects like control individuals without cognitive impairment.7 Thus, practice 
effects may not have significantly influenced the current data, because some degree of 
mild cognitive impairment is prevalent in individuals with sufficient and severe PD who 
present for DBS. However, because this effect is difficult to quantify, the potential 
influence of repeated exposure to stimuli in the present data remains unknown. In any 
case, potential improvements in some skills, as expected, circumscribed the decline in 
specific neurocognitive functions, and stable neuropsychiatric status indicates 
encouraging safety and feasibility outcomes for this procedure. 
DBS Plus 
The positive safety and feasibility results presented in this project provide the 
first prospective, proof-of-concept evidence for the strategy of combining a cellular or 
biological therapy that is delivered in conjunction with DBS, although several 
investigators have previously described the theoretical concept of combined therapy. 
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(During, Kaplitt, Stern, & Eidelberg, 2001; Rowland et al., 2016; Rowland et al., 2015) 
Meanwhile, in several cases, some patients received DBS therapy after receiving cell 
therapy (fetal transplant after the development of runaway dyskinesias). (Graff-Radford 
et al., 2006) 
We did not observe the development of off- or on-therapy dyskinesias in our 
patients through the course of our study or at any routine follow-up visits beyond the 
study timeline. Although it could be argued that the grafted tissue possibly caused the 
dyskinesias and the STN stimulation masked them, we did not observe any dyskinesias 
even during the 12 hours off stimulation at the testing time points. Thus, we report that 
tissue grafts can be implanted into the substantia nigra directly following the 
implantation of stimulating electrodes into the STN, and this adds minimal clinical risk 
for up to 1 year. Additionally, when performed in this manner, clinical evaluations for 
assessing graft function are straightforward and can be carried out easily and in 
accordance with current off-therapy protocols. Thus, we fully support the platform—
which we have termed DBS Plus—for studying cellular or biological disease-modifying 
therapies in patients who are candidates for DBS therapy. The main advantage to the 
patients is that they are able to receive the full benefits of DBS therapy while 
participating in a clinical trial. 
While it is possible that DBS therapy may influence graft function, as seen with 
the regional metabolic effects of DBS lead implantation, (Pourfar et al., 2009) we think 
that testing this cellular therapeutic approach in patients receiving DBS is important. The 
overall clinical goal of any PD therapy is to improve patient outcomes. Given the 
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complexity and clinical variability of PD, it is unlikely that a new therapeutic approach 
will directly result in a frontline, monotherapeutic treatment. Rather, a more likely 
process is that a new therapeutic approach will at first become an adjunctive therapy to 
current treatment strategies, much in the same way that DBS has become integrated 
into accepted adjunctive therapies for symptom control. If future studies show that an 
invasive, cellular, or biological approach could produce a disease-altering effect, then it 
could be appropriately tested in patients who are in earlier stages of illness. 
Although we are proponents of the DBS Plus platform, there are limitations. For 
our study, the main limitation is our inability to track the survival and biological influence 
of the graft on the host environment. At this stage, we can only draw on the results of 
Kordower et al., (Kordower, Fiandaca, Notter, Hansen, & Gash, 1990) who showed that 
sural nerve grafts to the nonhuman primate caudate and putamen contain surviving, 
nerve growth factor–rich Schwann cells at 3 months after grafting. As noted above, the 
ROI represented by the graft is very small and restricts the type of imaging, such as PET 
or SPECT scans, that could be beneficial. Because of the presence of the DBS system, 
MRI is limited to 1.5 T, and with some sequences, such as SWI series, the artifact 
produced by the stimulating electrode may obscure the graft ROI. Our ongoing studies 
(www.clinicaltrials.gov, registration no. NCT02369003) have addressed some of these 
issues by including participants who are receiving DBS to the globus pallidus internus, 
thereby freeing the ROI of the graft from lead artifacts. We have also added DaTscan 
imaging to the protocol to investigate the possibility of the graft’s influence on the nigral 
projections to the striatum. (Marek et al., 2001) Another overall limitation of our current 
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study is the inability to draw conclusions from the clinical efficacy data because of the 
small sample size. This is an expected limitation inherent in the design of this pilot study 
that focused on safety and feasibility. Other study design limitations include the lack of 
a control group and nonblinding, which does not take into account the possibility of the 
placebo effect on clinical measures. Furthermore, long-term follow-up will be required 
to fully assess the disease-altering capabilities, if any. 
 
Conclusions 
We present the results of our study in which we investigated the safety and 
feasibility of placing single, autologous, peripheral nerve grafts into the substantia nigra 
of patients with PD undergoing DBS therapy and report our clinical outcome measures. 
This study is unique in that it is the first to provide prospective data on using the DBS 
Plus platform that combines cellular therapy with DBS therapy, and this is the first study 
to evaluate the potential effects of peripheral nerve grafts on the progression of PD. We 
demonstrated that the procedure can be performed in a straightforward manner with 
minimal additional risk to patients for up to 1 year. In addition, we present preliminary 
evidence of the possible influence of the graft on motor measures (UPDRS part III) in the 
off state at 1 year. In the context of the inherent limitations of this pilot study design, 
we think that the overall positive findings presented here warrant further clinical 
investigation. 
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Chapter 4 Tables 
 
Case No. Event 
Significant 
Adverse Event Status Relatedness 
1 Urinary retention No Resolved DBS surgery 
2 Hypomania No Resolved Stimulation 
3 None NA NA NA 
4 Superficial 
cellulitis of ankle 
incision 
Yes Resolved Graft harvesting 
5 Cough No Resolved Not related 
 Headache No Resolved DBS surgery 
 Falls No Resolved Not related 
6 Fall & head 
laceration 
No Resolved Not related 
7 None NA NA NA 
8 None NA NA NA 
NA = not applicable. 
 
Table 4.1: Cumulative 1-year adverse events 
Summary of all clinical adverse events for study participants. 
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Variable 
Mean ± SD 
Baseline 12 Mos   
UPDRS   
 Part I* 2.6 ± 1.8 2.1 ± 1.7 
 Part II† 15.6 ± 3.7 14.5 ± 5.8 
 Part III‡ 32.5 ± 9.7 25.1 ± 15.9 
 Part III§ 13.4 ± 9.7 10.9 ± 9.7 
 Part IV¶ 5.5 ± 1.9 1.6 ± 2.3 
Other scales   
 Modified 
Hoehn & Yahr 
Scale** 
2.8 ± 0.5 2.8 ± 0.7 
 Schwab & 
England 
Activities of 
Daily Living 
Scale†† 
75.0 ± 9.3 81.3 ± 13.6 
 Parkinson’s 
Disease 
Questionnair
e-8‡‡ 
9.4 ± 4.4 7.5 ± 4.5 
* Mentation, behavior, and mood (range 0–16). 
† Activities of daily living while on therapy (range 0–52). 
‡ Motor examination while off therapy (range 0–108). 
§ Motor examination while on therapy (range 0–108). 
¶ Complications of therapy (range 0–23). 
** Measured while off therapy (range 0–5). 
†† Range 0–100. 
‡‡ Range 0–32. 
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Table 4.2: Participant scores 
The mean +/- SD UPDRS and other scale scores across all participants at baseline 
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Table 4.3: Individualized participant characteristics 
Parti
cipa
nt 
No. 
Age 
(yrs) 
Dura
tion 
w/ 
PD 
(yrs) 
UPDRS Score 
LED 
(mg) 
Modified 
Hoehn & 
Yahr 
Scale 
Activiti
es of 
Daily 
Living 
Scale 
Parkinson’s 
Disease 
Questionna
ire-8 Part I  
Part 
II  
Part 
III 
Part 
III 
Part 
IV 
Part 
IV 
1             
Base
line 
71 14 2 19 10 30 4 0 300 3 80 6 
12 
mos 
  5 18 13 32 0 0 0 4 60 8 
2             
Base
line 
64 13 3 20 18 31 7 2 1800 3 70 11 
12 
mos 
  3 19 10 23
§ 
2 0 0 3 90 6 
3             
Base
line 
55 6 6 9 30 48 8 3 900 3 70 17 
12 
mos 
  4 16 18 43 1 1 0 3 70 14 
4             
Base
line 
48 12 4 16 5 34 3 1 375 3 80 11 
12 
mos 
  1 5 0 8 0 0 0 2 100 0 
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Table 4.3 cont. 
5             
Base
line 
56 5 2 12 11 28 3 0 500 2 90 4 
12 
mos 
  1 21 7 17 0 0 0 2 90 6 
6             
Base
line 
75 14 3 18 6 28 6 3 1300 3 80 8 
12 
mos 
  2 11 6 17 1 1 225 3 80 5 
7             
Base
line 
65 6 1 16 3 17 7 1 1280 2 60 13 
12 
mos 
  1 18 3 9 7 2 600 2 90 13 
8             
Base
line 
69 8 0 15 24 44 6 1 380 3 70 5 
12 
mos 
  0 8 30 52 2 0 0 3 70 8 
* Baseline measurements were performed during the rising phase of the levodopa challenge. 
Measurements at 12 months were performed after the DBS had been on for at least 45 minutes 
and during the rising phase of the levodopa challenge (if applicable). 
† Baseline measurements were performed after the PD medications had been stopped for > 12 
hours. Measurements at 12 months were performed after the DBS had been off for > 12 hours 
and PD medications had been stopped for > 12 hours (if applicable). 
‡ Measures dyskinesia on a scale of 0–13.      § DBS had been off for only 3 hours at measurement. 
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Table 4.3: Individualized participant characteristics 
All UPDRS and other scale scores for each participant at baseline and 12 months later. 
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Table 4.4: Individual lateralized scores while off medication and/or off stimulation 
Participant 
No. 
Total Lateralized 
Scores* Tremor† Rigidity‡ Bradykinesia§ 
Ipsilat
eral 
Contra
lateral 
Ipsilat
eral 
Contra
lateral 
Ipsilat
eral 
Contra
lateral 
Ipsilat
eral 
Contra
lateral 
1         
 Baseline 8 10 3 0 2 2 3 8 
 12 mos 8 6 1¶ 0** 0¶ 0¶ 7†† 6¶ 
2         
 Baseline 7 11 3 5 0 0 4 6 
 12 mos 6 7 1¶ 0¶ 0** 2†† 5†† 5¶ 
3         
 Baseline 12 23 2 6 3 6 7 11 
 12 mos 12 19 2** 4¶ 2¶ 3¶ 8†† 12†† 
4         
 Baseline 10 12 4 7 0 2 6 3 
 12 mos 2 5 0¶ 2¶ 0** 1¶ 2¶ 2¶ 
5         
 Baseline 8 15 1 7 3 4 4 4 
 12 mos 5 7 1** 2¶ 2¶ 2¶ 2¶ 3¶ 
6         
 Baseline 7 11 0 2 1 1 6 8 
 12 mos 4 8 0** 2** 1** 2†† 3¶ 4¶ 
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Table 4.4 cont. 
7         
 Baseline 5 7 0 1 1 1 4 5 
 12 mos 3 4 0** 0¶ 1** 2†† 2¶ 2¶ 
8         
 Baseline 14 18 3 4 4 4 7 10 
 12 mos 20 14 4†† 0¶ 5†† 5†† 11†† 9¶ 
* Range 0–36. Includes tremor at rest, action or postural tremor of hands, rigidity, finger taps, 
hand movements, rapid alternating movements of the hands, and leg agility. 
† Range 0–12. Includes tremor at rest and action or postural tremor of the hands. 
‡ Range 0–8. 
§ Range 0–6. Includes finger taps, hand movements, rapid alternating movements of the hands, 
and leg agility. 
¶ Improved scores from baseline. 
** No change from baseline. 
†† Worse score from baseline. 
 
Table 4.4: Individual lateralized scores while off medication and/or off stimulation 
All UPDRS and other scale scores for the left and right of each participant at 
baseline and 12 months later. 
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Table 4.5: Neurocognitive measures of various neurocognitive domains and skills 
Neurocognitive Measures* Preop Mean ± SD Postop Mean ± SD 
Premorbid functioning & 
intelligence estimates 
  
 Premorbid status   
  Wide Range Achievement 
Test 4, word-reading subtest 
94.63 ± 16.60 95.05 ± 18.23 
 General intelligence   
  KBIT-2, intelligence quotient 
composite 
89.14 ± 16.94 88.43 ± 14.91 
 Verbal intelligence   
  KBIT-2, verbal 88.57 ± 16.32 86.86 ± 14.92 
 Nonverbal & perceptual 
intelligence 
  
  KBIT-2, nonverbal 90.71 ± 20.06 90.71 ± 16.76 
Verbal learning & memory   
 List-based learning   
  HVLT-R, total recall 81.37 ± 15.01 78.38 ± 15.57 
 List-based recall   
  HVLT-R, delayed recall 85.63 ± 18.70 79.25 ± 20.19 
 List-based recognition memory   
  HVLT-R, recognition 
discrimination index 
97.12 ± 10.37 84.50 ± 33.02 
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Table 4.5 cont. 
 Story-based learning   
  WMS-IV, logical memory I 89.29 ± 16.94 85.71 ± 14.27 
 Story-based recall   
  WMS-IV, logical memory II 81.14 ± 16.29 89.29 ± 13.97 
Expressive & receptive language   
 Confrontation naming   
  Boston Naming Test–2nd 
Edition 
87.43 ± 25.08 84.71 ± 25.34 
 Semantic fluency   
  Animal fluency 92.38 ± 17.24 79.63 ± 13.55 
 Phonemic fluency   
  Controlled Oral Word 
Association Test 
91.29 ± 15.81 75.43 ± 12.56† 
 Expressive vocabulary   
  WAIS-IV, vocabulary subtest 113.33 ± 7.64 102.50 ± 8.66 
 Auditory comprehension   
  Multilingual Aphasia 
Examination, token test 
98.00 ± 17.94 93.14 ± 19.80 
Visuospatial skills   
 Spatial perception   
  Benton Judgment of Line 
Orientation 
89.63 ± 17.25 94.88 ± 21.38 
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Table 4.5 cont. 
 Constructional praxis   
  WAIS-IV, block design 
subtest 
90.00 ± 18.03 95.00 ± 18.03† 
Attention & executive functions   
 Attention & working memory   
  WAIS-IV, digit span subtest 95.00 ± 8.45 93.75 ± 12.17 
 Mental flexibility & divided 
attention 
  
  TMT-B 82.57 ± 33.22 85.17 ± 20.60 
 Response inhibition   
  Stroop, color-word 91.29 ± 12.54 82.29 ± 18.25 
  Stroop, interference 106.29 ± 10.31 100.29 ± 16.61 
 Abstract problem solving   
  WCST-64, total error rate 77.71 ± 15.53 85.43 ± 17.82 
  WCST-64, perseverative 
error rate 
86.43 ± 14.07 83.14 ± 19.83 
  WCST-64, nonperseverative 
error rate 
76.86 ± 15.55 95.86 ± 13.23 
  WCST-64, categories 
completed* 
1.57 ± 1.27 2.14 ± 1.77 
Information processing speed   
 Verbal speed   
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Table 4.5 cont. 
  Stroop, word reading 82.14 ± 14.65 79.71 ± 15.01 
  Stroop, color naming 79.57 ± 8.92 75.57 ± 15.24 
 Psychomotor speed   
  TMT-A 83.86 ± 21.08 85.29 ± 15.73 
Emotional functioning   
 Psychiatric symptoms   
  Psychiatric Diagnostic 
Screening Questionnaire, total 
score* 
21.29 ± 25.02 26.50 ± 27.36 
HVLT-R = Hopkins Verbal Learning Test–Revised; KBIT = Kaufman Brief Intelligence Test; TMT = 
Trail Making Test; WAIS-IV = Wechsler Adult Intelligence Scale–Fourth Edition; WCST-64 = 
Wisconsin Card Sorting Test–64 Card Version; WMS-IV = Wechsler Memory Scale–Fourth Edition. 
* Values are provided as standard index scores with a mean ± SD of 100 ± 15 unless otherwise 
noted with an asterisk. 
† Significant at p < 0.05. 
 
Figure 4.5: Medication Reduction Following Surgery 
Mean and SD (error bars) LEDs were significantly lower at 12 months postoperatively than 
before surgery. L-DOPA = levodopa. 
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Chapter 4 Figures 
Figure 4.1: Graft Locations in All Participants 
 
 
Figure 4.1: Graft Locations in All Participants 
Axial T2-weighted MR images obtained at 12 months in all participants, showing the area 
targeted for graft implantation (arrows). Asterisks indicate DBS electrode locations. 
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Figure 4.2: Motor Score Changes in All Participants 
 
 
Figure 4.2: Motor Score Changes in All Participants 
Individual changes in motor scores (UPDRS part III) while off DBS and off medication 
therapy from baseline to 12 months after surgery. Minimal (2.5 points), moderate (5.2 
points), and large (10.8 points) CIDs are indicated. Each symbol represents a different 
participant. Figure is available in color online only. 
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Figure 4.3: Average Improvement or Worsening in Motor Deficit Scores 
 
 
Figure 4.3: Average Improvement or Worsening in Motor Deficit Scores 
For each of the domains of the UPDRS part III test, the total change in points for all 
participants was combined. The changes in the scores for all participants who performed 
worse in each domain were combined, and the changes in scores for all participants who 
showed improvements in each domain were combined. 
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Figure 4.4: Average Improvement or Worsening in Lateralized Motor Score 
 
 
Figure 4.4: Average Improvement or Worsening in Lateralized Motor Score 
Lateralized scores on the UPDRS part III test were used to identify differences in motor 
performance on the side contralateral or ipsilateral to graft placement. The changes in 
the scores of all participants who performed worse on the lateralized test were combined, 
and the changes in scores of all participants who showed improvements on the lateralized 
test were combined. Lateralized scores include tremor at rest, action or postural tremor 
of hands, rigidity, finger taps, hand movements, rapid alternating movements of the hand, 
and leg agility. 
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Figure 4.5: Medication Reduction Following Surgery 
 
 
Figure 4.5: Medication Reduction Following Surgery 
Mean and SD (error bars) LEDs were significantly lower at 12 months postoperatively than 
before surgery. L-DOPA = levodopa. 
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Chapter Five: Conclusions 
Research Summary and Implications for the DBS Plus Clinical Trial 
Summary of Findings 
Histology of the human sural nerve tissue supports the nerve fascicle composition 
of the nerve graft used in the DBS Plus clinical trial. RNAseq analysis showed 
transcriptome changes between the injury naive (Stage I) and the injury conditioned sural 
nerve (Stage II) samples in all six patients analyzed. Consistent changes in all six patients 
were seen in gene ontologies of myelin production, growth factor activity, Schwann cell 
dedifferentiation, negative regulation of neuron death, and negative regulation of 
apoptosis. All of these changes were consistent with literature descriptions of the 
peripheral nerve repair process, including Schwann cell transdifferentiation, immune cell 
infiltration, and myelin clearance.  
The Avatar animal model development has demonstrated the feasibility of using 
athymic nude rats as a host for human peripheral nerve tissue grafts in the brain. 
Preliminary results show that the human graft cells survive in the brain for at least six 
months. The animal model has potential applications for a dopamine lesion or other PD 
model paradigms such as alpha synuclein overexpression viral vectors, further histology, 
and/or in vivo transcriptome analysis. 
The clinical trial data supports the safety and feasibility of the grafting procedure. 
Participants who received the graft have showed an overall decrease in the severity of 
their PD motor symptoms when off DBS stimulation and off medication. With the 
121 
expected increase in severity of motor symptoms over time in PD, these results suggest 
that the sural nerve grafting procedure may have benefits in reducing the severity and 
progression of PD motor symptoms. 
Discussion 
These results support the clinical trial’s goal of delivering reliably pro-regenerative 
peripheral nerve tissue to the substantia nigra of patients with Parkinson’s disease. In 
addition to elucidating transcriptome changes in human peripheral nerve injury response, 
the RNAseq analysis identified the consistency of transcriptome changes between 
multiple patients, which supports the reliability of the pre-lesioning approach to nerve 
conditioning used in the clinical trial. The Neuro-Avatar model demonstrates that both 
the injury-naive and injury-conditioned nerve tissue survives within the CNS. The clinical 
data supports the safety and feasibility of this procedure and provides preliminary 
evidence for efficacy in reducing the severity of the motor symptoms of PD. 
This work also revealed unexpected findings. Before performing histology on the 
nerve grafts it was assumed that the surgical dissection of the nerve separated fascicles 
completely. Histology revealed that the many of the dissected nerve pieces contained 
multiple fascicles connected by perineurium. With the RNAseq transcriptome analysis the 
researchers had expected several transcription factors (namely NRF2, c-Jun, and NFkB) to 
be upregulated. This was not the case, as each of these genes was not significantly 
differentially expressed between samples. However, the magnitude of some gene 
ontology changes, for example 100% of differentially expressed “Negative Regulation of 
122 
Apoptotic Processes” (anti-apoptosis) genes being upregulated was an surprising but 
intriguing results of the pre-lesioning method of conditioning nerve tissue. 
With respect to the advantages of the pre-lesioning approach, the RNAseq 
analysis demonstrates pro-regenerative changes within the injury-conditioned nerve 
tissue. It is still an open question as to whether the nerve tissue would adopt pro-
regenerative phenotype if the injury-naive tissue were to be implanted in the CNS. The 
survival of injury-naive tissue for six months in the Neuro-Avatars suggests that the injury-
naive tissue adapts to the environment of the CNS. It is possible that grafting injury-naive 
nerve tissue would also have therapeutic benefit in this clinical trial. 
Thus, this dissertation work has identified an open question: would injury-naive 
tissue be an equally effective alternative to the injury-conditioned tissue currently grafted 
in the clinical trial? 
The case for the pre-lesioning approach 
The pre-lesioning approach used in this clinical trial aims to make use of the most 
neuro-regenerative tissue found in the human body. Many factors interact in peripheral 
nerve to facilitate the regeneration of peripheral axons and functional recovery after 
injury. In addition to Schwann cells, peripheral nerve tissue contains a matrix of 
connective tissue, fibroblasts, and macrophages. These elements respond to peripheral 
nerve injury in a coordinated fashion to promote functional regeneration. Removing 
peripheral nerve from this environment, as would be the case when grafting injury-naive 
tissue, may interrupt these process. For example, macrophages may not successfully 
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infiltrate the nerve tissue if removed and implanted into the brain, where it would be 
disconnected from vasculature. 
Secondly, and more importantly, the clinical trial has already demonstrated the 
safety and feasibility of this approach. Preliminary results from the clinical trial also 
support the potential efficacy of the injury-conditioned graft tissue in reducing the 
severity of motor symptoms as assessed by UPDRS Part III Motor Score. (Figure 4.2) 
The case for the injury naive approach 
Currently DBS surgeries at other institutions are staged differently than at the 
University of Kentucky. Most groups implant the stimulating electrodes during the first 
stage of the surgery, then connect the electrodes to a stimulator in the second stage. The 
nerve grafts must be implanted at the same time as DBS electrodes in order to take 
advantage of surgical access to deep brain structures. Thus, applying a pre-lesioning 
approach at other institutions is less feasible, because the pre-lesioning cannot occur 
during DBS surgeries. 
In addition, there is some additional medical risk of accessing the site of peripheral 
nerve collection multiple times. One case of superficial cellulitis at of the lateral ankle 
following a second nerve collection was observed in the clinical study. Though it was 
quickly resolved without incident, it constitutes an adverse event  
When considering efficacy, figures 5-1 and 5-2 highlight that patients 4 and 2 
experienced the most significant changes in patient motor symptoms. Of note, patient 4 
exhibited a different pattern of sural nerve transcriptome change between Stage I and 
Stage II as visualized in the correlation matrix (Figure 2-2A). Patient 4 exhibited a 
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transcriptome more similar to Stage I tissue. While only a single instance, this finding 
suggests that peripheral tissue with a more injury-naive transcriptome is potentially 
effective in reducing the severity of motor symptoms when grafted into the SN of patients 
with PD. 
Implications for the clinical trial 
These observations taken together support the development of an arm of the 
clinical trial testing the use of injury-naive nerve grafts. The more challenging option (pre-
lesioning the graft tissue by two weeks) has already been done in over 60 patients. Phase 
I clinical trials demonstrate safety and feasibility. It would be appropriate to evaluate the 
feasibility of using injury-naive tissue grafts before proceeding to a Phase II clinical trial 
evaluating efficacy. When considering efficacy, a demonstration of non-inferiority would 
make using injury-naive tissue more feasible than injury-conditioned nerve tissue. A 
randomized cohort of participants who would receive DBS alone would be an ideal 
comparison for efficacy measures related to disease progression. 
A lesson from this clinical trial is that translational research aiming to be applied 
in humans is best conducted in humans. Properly designed in vitro experiments and 
animal models can answer some questions, but ultimately questions of human safety, 
feasibility, and efficacy can only be answered in humans. Finite resources for clinical trial 
research and development must balance groundwork with application. With this in mind, 
a comparison group within the clinical trial would be best answer the question of the 
relative safety, feasibility, and efficacy of injury-naive nerve graft tissue versus injury-
conditioned nerve graft tissue. 
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Future Research Directions 
PN tissue as a source of cell-based therapy for neurodegenerative diseases shows 
great promise. PN tissue may have the ability slow down the progression of 
neurodegenerative diseases and contribute in the future to a disease modifying therapy. 
Modification of peripheral nerve tissue to improve this therapeutic potential merits 
further research. Further work is needed to test how manipulating PN tissue could deliver 
vital therapeutic agents to CNS neurons to stop or reverse the degenerative processes. 
In the future we hope to continue the animal model work with Parkinsonian 
models such as dopamine depletion using 6-OH dopamine or alpha synuclein 
overexpression using viral vectors. In addition, evaluating biological processes such as 
axon growth, myelination by grafted Schwann cells, and growth factor activity may reveal 
more about the biological behavior of the graft tissue in the CNS. 
With analysis of more patient tissue we could further correlate clinical disease 
progression with the graft tissue transcriptome. This approach could identify undescribed 
neuroprotective genes in a data-driven manner. Future study of human graft recipients 
after autopsy can also answer questions about the biological activity of the graft. If 
possible, RNA sequencing of the graft tissue in situ would reveal much as to the behavior 
of the peripheral nerve tissue after grafting into the CNS. 
Conclusion 
From this work we have validated the consistent response of human patients to a 
conditioning injury of peripheral nerve used as grafts to the CNS. This work has also 
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described the pro-regenerative phenotype of pre and post-injury peripheral nerve tissue 
at a transcriptome scale. We have also developed an animal model of the grafting 
procedure that demonstrates survival of human nerve tissue in the brains of 
immunodeficient rats for at least six months. The ongoing clinical trial can provide future 
insights into the safety, feasibility, and efficacy of peripheral nerve grafts for the 
treatment of PD and other neurodegenerative disorders. 
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Chapter 5 Figures 
 
Figure 5.1: UPDRS Part III Motor Score of RNAseq-Analyzed Graft Recipients 
UPDRS scores of participants who received graft tissue analyzed by RNAseq. A higher 
score more severe motor symptoms. 
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Figure 5.2: UPDRS Part III Motor Score Change of RNAseq-Analyzed Graft Recipients 
Changes of UPDRS scores from baseline of participants who received graft tissue analyzed 
by RNAseq. A reduction of score indicates an improvement in motor symptoms. 
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